US20120203465A1 - Systems, methods and program products for collecting and organizing health data - Google Patents
Systems, methods and program products for collecting and organizing health data Download PDFInfo
- Publication number
- US20120203465A1 US20120203465A1 US13/397,360 US201213397360A US2012203465A1 US 20120203465 A1 US20120203465 A1 US 20120203465A1 US 201213397360 A US201213397360 A US 201213397360A US 2012203465 A1 US2012203465 A1 US 2012203465A1
- Authority
- US
- United States
- Prior art keywords
- test
- data
- central computer
- group
- test data
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000036541 health Effects 0.000 title claims abstract description 39
- 238000000034 method Methods 0.000 title description 21
- 238000012360 testing method Methods 0.000 claims abstract description 451
- 238000005259 measurement Methods 0.000 claims abstract description 132
- 239000000090 biomarker Substances 0.000 claims abstract description 117
- 210000001124 body fluid Anatomy 0.000 claims abstract description 109
- 210000002700 urine Anatomy 0.000 claims description 44
- 230000015654 memory Effects 0.000 claims description 39
- 230000008859 change Effects 0.000 claims description 24
- 239000000126 substance Substances 0.000 claims description 19
- 238000004891 communication Methods 0.000 claims description 18
- 230000036542 oxidative stress Effects 0.000 claims description 15
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 230000004044 response Effects 0.000 claims description 10
- 206010061218 Inflammation Diseases 0.000 claims description 7
- 241000208125 Nicotiana Species 0.000 claims description 7
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 7
- 230000004054 inflammatory process Effects 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 238000004590 computer program Methods 0.000 claims description 3
- 238000012423 maintenance Methods 0.000 claims description 3
- 238000009535 clinical urine test Methods 0.000 claims 2
- 239000000523 sample Substances 0.000 description 52
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 34
- 230000008901 benefit Effects 0.000 description 33
- 239000003963 antioxidant agent Substances 0.000 description 22
- 235000006708 antioxidants Nutrition 0.000 description 22
- 230000003078 antioxidant effect Effects 0.000 description 21
- 230000005484 gravity Effects 0.000 description 18
- 229940109239 creatinine Drugs 0.000 description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 11
- 238000010606 normalization Methods 0.000 description 10
- 230000004792 oxidative damage Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 7
- 230000003287 optical effect Effects 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 229960003180 glutathione Drugs 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000000524 Thiobarbituric Acid Reactive Substance Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 3
- 210000003423 ankle Anatomy 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 229940118019 malondialdehyde Drugs 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 230000037081 physical activity Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 210000000707 wrist Anatomy 0.000 description 3
- JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- -1 Lipid hydroperoxides Chemical class 0.000 description 2
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000004422 calculation algorithm Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000004737 colorimetric analysis Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 238000013101 initial test Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000010295 mobile communication Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 238000007639 printing Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 210000003296 saliva Anatomy 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- PXGPLTODNUVGFL-BRIYLRKRSA-N (E,Z)-(1R,2R,3R,5S)-7-(3,5-Dihydroxy-2-((3S)-(3-hydroxy-1-octenyl))cyclopentyl)-5-heptenoic acid Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC=CCCCC(O)=O PXGPLTODNUVGFL-BRIYLRKRSA-N 0.000 description 1
- YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 description 1
- NNDIXBJHNLFJJP-UHFFFAOYSA-N 20-Hydroxyeicosatetraenoic acid Chemical compound OCCCCCC=CCC=CCC=CCC=CCCCC(O)=O NNDIXBJHNLFJJP-UHFFFAOYSA-N 0.000 description 1
- QZDHOBJINVXQCJ-UHFFFAOYSA-N 3-[4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimido[1,2-a]purin-10-one Chemical compound C1C(O)C(CO)OC1N1C(N=C2N(C=CC=N2)C2=O)=C2N=C1 QZDHOBJINVXQCJ-UHFFFAOYSA-N 0.000 description 1
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000003966 Alpha-1-microglobulin Human genes 0.000 description 1
- 101800001761 Alpha-1-microglobulin Proteins 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 208000031911 Multiple Chronic Conditions Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- IOVCWXUNBOPUCH-UHFFFAOYSA-M Nitrite anion Chemical compound [O-]N=O IOVCWXUNBOPUCH-UHFFFAOYSA-M 0.000 description 1
- 102000012404 Orosomucoid Human genes 0.000 description 1
- 108010061952 Orosomucoid Proteins 0.000 description 1
- 102000004264 Osteopontin Human genes 0.000 description 1
- 108010081689 Osteopontin Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000011481 absorbance measurement Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 238000011325 biochemical measurement Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000010267 cellular communication Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019506 cigar Nutrition 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 238000013500 data storage Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 235000021158 dinner Nutrition 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000001624 hip Anatomy 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000002432 hydroperoxides Chemical class 0.000 description 1
- TUJKJAMUKRIRHC-UHFFFAOYSA-N hydroxyl Chemical compound [OH] TUJKJAMUKRIRHC-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 150000002535 isoprostanes Chemical class 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 230000027939 micturition Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000012502 risk assessment Methods 0.000 description 1
- 102220335514 rs762212949 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000000276 sedentary effect Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000005586 smoking cessation Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019195 vitamin supplement Nutrition 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7004—Stress
- G01N2800/7009—Oxidative stress
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7095—Inflammation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/17—Nitrogen containing
- Y10T436/173076—Nitrite or nitrate
Definitions
- Fields of the invention include systems, methods and program products for collecting, and organizing health data. Another field is wellness data determination.
- Health of individuals is important for obvious reasons. Individuals often seek medical advice for diagnosis of disease and as an aid in the evaluation of an individual's overall health and wellness (e.g. as part of a periodic check-up). Unfortunately, consultation with medical professionals often has an economic cost associated with it that limits access for many.
- One example embodiment of the invention is a system for collecting, measuring and outputting health data.
- the system comprises a plurality of test readers that each determine a plurality of different bodily fluid measurements in a bodily fluid sample and that generate a test data set for each bodily fluid sample that comprises the plurality of different biomarker measurements and communicate the test data sets over a network.
- a central computer is linked to each of the plurality of test readers over the network and receives the test data set and stores the test data sets in a memory, the central computer associating at least a first security key with the test data set.
- the central computer responds to a first request for a test output report received over a network that includes the first security key by communicating a test output report that includes a plurality of bodily fluid test measurements and transmits it over the network.
- Another example embodiment comprises a computer program product comprising executable instructions stored in a non-volatile non-transitory memory (with examples including but not limited to magnetic, chemical and optical memory media), the instructions when executed causing one or more computers to execute steps comprising: receive a plurality of individual test data sets over a network from test readers that are connected to the network, each of the plurality of test data sets generated from a bodily fluid sample taken from an individual and including bodily fluid measurement data for at least three different biomarkers that are useful to estimate oxidative damage, antioxidant capacity, and inflammatory status; store the plurality of data sets in a memory; associate a plurality of the test data sets with a first security key that corresponds to a related group in the memory; receive over a network a first request for a group output report, the request including the first security key; use the first security key to identify from the memory the plurality of test data sets that correspond to the group; calculate averages for each of the bodily fluid measurements from all of the test data sets that correspond to the group; and prepare a
- FIG. 1 is a schematic that is useful to illustrate some invention embodiments
- FIG. 2 is a schematic illustration of a bodily fluid test panel device of a system of the invention
- FIG. 3 is a representation of a sample test output report of an invention embodiment
- FIG. 4 is a representation of sample data stored by an invention embodiment
- FIG. 5 is a flowchart illustrating steps performed by an example system or program product of the invention.
- the invention may be embodied in one or more of a system, method, software, or program product. Accordingly, it will be appreciated that in describing one example embodiment of the invention, description of other embodiments may likewise be had. As an example, when describing a system of the invention, description of a method, software or program product may also be had. Additionally, a method of the invention may be carried out by a system of the invention, and a program product of the invention may be stored on one or more non-volatile memories linked to a system of the invention that when executed cause the system to carry out a method of the invention.
- Example systems, methods and program products of the invention are directed to collecting, storing, processing, and outputting health data.
- a system can be provided for collecting, storing, processing and outputting data obtained from measurements performed on bodily fluid samples from individuals, with or without additional information on the individual (such as height, weight, age, gender, lifestyle and health history data that may be input manually or electronically populated and is incorporated into the complete record for a specific test) in a highly efficient manner to provide a useful indication of the individual's overall health, wellness and/or relative risk for contracting one or more illnesses.
- the bodily fluid sample is contained in a test sample holder, which may contain discrete components for the measurement of multiple substances in bodily fluids for convenience and to reduce time and expense.
- Resulting test data is measured by a device which may be comprised of a single physical unit or multiple separate components for the measurement of biomarker(s) and for the control of certain aspects of the function of the measurement component and for computation of the results, processing of an on-site report, and transmission of data to a central computer, stored, processed by a central computer.
- Resultant test reports can be provided to individuals and others in a variety of useful and customizable formats.
- test results are stored over time so that individuals and others can measure changes in the levels of biomarkers and other metrics of health and wellness over time.
- the tests and results are particularly well suited for estimating an individual's overall wellness, which may be thought of as health and/or resistance to one or more chronic diseases.
- pluralities or even multiplicities of individuals that are related to one another to form a group can have their test data organized, analyzed, and otherwise treated as a group.
- This provides some powerful and useful advantages and benefits over the prior art.
- One example group is a selected general demographic category(s) (any combination of age, geographic location, gender, lifestyle profiles), another may be employees of a particular employer or students from a particular school, and others are combinations of these (e.g., all women between ages of 35-40 that are employees of a particular company).
- Such groups can obtain an overall health profile for their members, map it over time, compare individuals or group averages to other selected groups or universes, and in some embodiments make predictive projections of health care costs, incidences of particular diseases and other predictions.
- test panel device 10 may include urine, feces, blood, saliva or other bodily fluid sample, or some residue thereof, and may include a DNA sample.
- the bodily fluid test panel device 10 includes (or is) a dip stick cartridge that supports, contains or otherwise holds one or more urine dip sticks having multiple discretely arranged testing channels or test pads, each of which is embedded with reagents that react with different biochemical components in the bodily fluid sample such as urine.
- test panel device test panel device 10 configurations include (but are not limited to) a microfluidic or a lateral flow immunoassay device and the like.
- a microfluidic or a lateral flow immunoassay device When testing bodily fluids other than urine (with examples including saliva and blood), other configurations may be desirable.
- Urine offers advantages in many embodiments since its collection is relatively easy and noninvasive, collection and handling poses minimal infectious disease risk to participants and operators of the testing system and since urine provides sufficient volume for multiple assays. Urine specimens are well suited for large studies because they can be collected and stored by participants, costs of collection are relatively low, and compliance is high.
- a test subject such as a person (not illustrated) may provide a urine sample that is communicated to the bodily fluid test device 10 through immersion, dropwise addition, capillary flow, or other manner.
- the bodily fluid test device 10 includes a plurality of reagents that react with a plurality of different biochemical components of urine.
- biomarker as used herein broadly refers to a substance or group of substances in a biological sample that is (are) associated with a specific disease or condition, with an example being glucose in urine being associated with a hyperglycemic condition of a diabetic individual.
- a bodily fluid test panel device 10 may be comprised of test pads or channels that discretely measure the levels of two biomarkers, in others three biomarkers, others four biomarkers, others five biomarkers, others six biomarkers, others seven biomarkers, and others additional numbers of biomarkers. Including a plurality of different biomarkers on a single bodily fluid test device 10 provides advantages related to efficiency of time, cost, effort and others.
- the bodily fluid test panel device 10 may be provided in any number of different mechanical, chemical and/or immunochemical configurations in different invention embodiments. As indicated above, in some embodiments it may include a polymer cartridge containing a urine dipstick. Many aspects of the science of bodily fluid testing, with urine testing being one example, are generally well understood by those knowledgeable in the art and these aspects need not be detailed herein and will not be for sake of brevity. A brief summary of relevant aspects, however, is provided for completeness.
- a dry chemical media is provided and attached, held by, supported by or otherwise contained in or on a plastic frame or holder.
- the dry chemical media may include a dry carrier such as paper, powder (which may be compressed into a solid), pad, gel, glass or plastic fiber or other media that is loaded, embedded, impregnated or otherwise carries one or more reagents which, when exposed to a bodily fluid such as urine, will react to produce a detectable (and in many embodiments a quantitatively measurable) change in physical property.
- the reaction product results in a color change.
- Other examples of physical changes include fluorescence and a change in redox potential.
- the bodily fluid test device 10 provides for convenient testing of a plurality of different biomarkers in a single test. Accordingly, some test panel device 10 include different reagents arranged in a particular spatial order with discrete sections to allow for measurement of different biomarkers from a single bodily fluid sample.
- FIG. 2 is a schematic of one example test panel device 10 in which five individual test pads 12 are arranged in a particular spatial order along the length of the test panel device 10 .
- a single test pad may be embedded with different reagents in a discrete spatial arrangement to provide a similar result.
- the entire test panel device 10 may be exposed to a single bodily fluid sample (through dipping, dropwise addition, spraying, other fluidic transfer, or other).
- adjustments are made to account for the concentration of the urine specimen.
- concentration of biomarkers in urine specimens can depend on an individual's hydration status, time since last urination, and other factors.
- test subjects may be directed to follow certain instructions prior to fluid sample collection, such as not urinating for at least 30 minutes prior to the sampling, restricting the intake of fluids on the day (or other period of time) in which the sample is to be obtained, avoiding caffeinated beverages, following other dietary guidelines for a particular time period, and the like.
- some embodiments further include quantitative measurement of a parameter associated with urine concentration.
- Some invention embodiments may measure the creatinine level in a urine sample and/or the specific gravity of the sample as an indicator of the relative concentration of the sample.
- Urine specific gravity is the ratio of the density of a urine specimen to the density of water, and increases with solute concentration. It can be measured, for example, by refractometry. Alternatively, dry chemistry technology can be used in which a change in color is directly proportional to the specific gravity of the sample at a given pH value.
- Creatinine is a byproduct of muscle activity, and is cleared from the bloodstream by the kidneys and excreted in urine. Urinary creatinine concentrations can be determined by colorimetric assay, and analyte concentrations are usually reported as a ratio of the analyte concentration to creatinine concentration. Creatinine is typically present in urine in a generally known range. Likewise, urine typically has relatively known specific gravity ranges, and the average specific gravity of random urine specimens for individuals within a population have been reported (e.g. 1.020 for North
- Embodiments of the invention can measure one or more of these and use the measurement to estimate urine concentration.
- the measurement is used as a pass/fail determination—if in an allowed range the sample is deemed acceptable and vice versa, but no changes to the bodily fluid measurements are made.
- bodily fluid measurements are adjusted or normalized based on the estimated urine concentration.
- the concentration of creatinine in the specimen is measured using a discrete dry chemistry test pad, the general compositions of which are known and need not be discussed in detail herein for sake of brevity. If the creatinine concentration falls within a specified range, then the measured values for all of the biomarkers measured by the test panel device 10 are divided by the concentration value obtained for creatinine and may be expressed in common units such as micrograms/milligram of creatinine. In this embodiment, if the concentration of creatinine is below a specified value (e.g.
- the sample may be considered too dilute to permit accurate analysis of the biomarkers therein, and a report may be generated indicating that the sample is too dilute and that the subject should provide another sample at a later time to permit more accurate analysis.
- an upper limit may also be specified to improve accuracy since the relationship of the color produced in typical creatinine dry chemistry technologies is logarithmically related to the concentration of the specimen such that the change in color approaches a plateau value at high levels of creatinine.
- a report may be generated indicating that the sample is too concentrated to permit accurate measurement of biomarkers, (b) the operator may dilute and reanalyze the sample, or (c) a fixed high creatinine value may be used for normalization of concentrated specimens.
- the specific gravity measured by refractometry or by a discrete channel or dry chemistry test pad or other method, the general steps of which are well established and need not be discussed herein for sake of brevity, is used for normalization.
- an additional test pad or channel may be included in the test panel device 10 to measure the pH of the specimen, and this value may be applied to mathematically correct the apparent specific gravity measurement for improved accuracy of the normalization process in some but not all embodiments.
- a specified range e.g.
- the measured values for all of the biomarkers measured by the test panel device 10 are normalized based on the specific gravity measurement in some but not all embodiments.
- One algorithm that may be employed is to adjust the value obtained for each biomarker to that which would be observed in a sample with the specific gravity of the population norm.
- the sample concentration value is multiplied by (1.020 ⁇ 1.0)/(the specific gravity of the sample ⁇ 1.0), so that for a specimen with a specific gravity of 1.010, the normalized value of a biomarker would be twice that of the measured value.
- the example bodily fluid test device 10 also includes a unique identifier (“ID”).
- ID unique identifier
- test panel device 10 Because most applications for invention embodiments will be related to health and medical testing, it can be important to maintain a reliable and secure chain of identity—to ensure that the bodily data obtained using the test panel device 10 is correctly associated with an individual subject that provided the bodily fluid and to ensure that the privacy of test results can be maintained. It is also useful to provide for the recognition by the test reader 16 of specific lot numbers of test panel devices 10 , which may be valuable to avoid an operator using an expired lot, to reduce the possibility of inferior counterfeit test panel device 10 devices, to allow for lot-specific adjustments to standard curves or other parameters.
- the identifier encodes the nature and order of the dry chemistry or other analytical components and signals that the reader should analyze the reflectance or other physical change at specified wavelengths after specified time intervals.
- each test panel device 10 with a unique ID which can be recorded at the time of bodily fluid submission (or another time) and related to an individual test subject's name and/or other personal or identifying information.
- unique ID's can be provided with different invention embodiments. These include, but are not limited to, alphanumeric strings, one two or other dimensional barcodes, other optical means, radio frequency identifiers, and others.
- the schematic of FIG. 2 illustrates one example unique ID 14 in the form of an optical bar code. Although the example ID 14 is illustrated on the same surface as the pads 12 , in some embodiments it may be useful to orient it on the opposite or another different surface for compactness.
- the bodily fluid test device 10 is submitted to a test reader 16 for measurement of the concentrations of a set of biomarkers in a bodily fluid.
- the test reader 16 may be configured in many different manners in different invention embodiments.
- a test reader may be a dedicated electronic device that is connected to a processor based device such as a computer that controls it, records the resultant data as well as other biometric information that may be manually or electronically added to the file, performs the normalization, generates a report for that sample.
- the connection may be through a traditional BUS or other analog/digital connection.
- a different test reader may be integral with a computer, or may otherwise include a processor, memory, display and other computer related components. Many other potential test readers are contemplated in other embodiments.
- a test reader may be a highly compact, portable and wireless handheld device that optically scans a test panel device 10 .
- test reader is illustrated as a stand-alone electronic device 16 A connected to a separate computer 16 B.
- the computer 16 B may be a traditional commercial laptop or other computer that includes one or more processors, a non-volatile (such as a magnetic or optical memory) and volatile memory(s) (such as a RAM memory), data input such as a keyboard, mouse, disk drive, optical reader or other device, display such as a monitor, microphones, cameras, speakers and the like.
- the computer 16 B may be executing a program product of the invention, a client incidence of a client-server program product of the invention, or other program product.
- the computer 16 B may also be a dedicated computer that has been configured only to operate within the scope of the invention. Because the test reader 16 A and associated computer 16 B operate in conjunction and in some embodiments are integral with one another, reference herein to “test reader” will be understood to include reference to both a test reader 16 A and computer 16 B and/or a test reader 16 A or computer 16 B that includes the functionality of the other.
- the test reader 16 finds utility in portability. Portability allows for convenient use in applications such as mobile testing, for example. In an example application, employees at an office, factory or other location may be tested. Portability of test reader 16 allows for convenient use in such applications, with a test operator traveling to the location and administering tests on site. This is particularly useful in applications that include testing of bodily fluid samples that have a relatively short time window of accuracy, with an example being many urine biomarker applications. In some urine testing embodiments, depending on the urine dipstick and other technology used, the sample may be refrigerated or treated with a preservative to impede bacterial growth.
- testing is performed within 1 hour, within 2 hours, within 3 hours, within 4 hours, or within other time limits. Portability helps address related issues since urine samples can be obtained on-site for groups and the like.
- the test reader 16 may operate in any number of different functional manners suitable for performing different bodily fluid measurements.
- the term “bodily fluid measurements” is intended to broadly refer to measuring some aspect of a bodily fluid, including but not limited to measuring a biomarker contained within the bodily fluid, whether measured directly or indirectly.
- a bodily fluid measurement includes a quantitative or semi-quantitative measurement of the presence or concentration of a biomarker.
- a quantitative measurement is intended to broadly refer to one in which a relatively accurate numerical value (e.g., for a concentration) is determined, and a semi-quantitative measurement is one in which an approximate numerical value (e.g., for a concentration) can be estimated.
- Other embodiments include making qualitative measurements in which no numerical value is determined, but instead a determination is made regarding a quality indicator (e.g., color, pass/fail, presence/absence, other).
- test reader 16 there are a multitude of potential manners of operation of different test readers of the invention to perform a bodily fluid measurement. Many aspects of the technical operation of a reader suitable for use in invention embodiments are known in the art and need not be detailed herein.
- the configuration of a particular test reader will depend necessarily on the configuration of the bodily fluid test panel device 10 .
- a cooperating relationship exists between the test panel device 10 and test reader 16 —the test reader 16 necessarily is configured to measure concentration indicators that the test panel device 10 is configured to indicate, and in particular to cooperate with the biomarker to be measured.
- One example bodily fluid test reader 16 and cooperating test panel device 10 exploits chemical reagents embedded in the test panel device pads 12 ( FIG. 2 ) that react with particular biomarkers within a bodily fluid components to produce a color change, with particular color indicative of the biomarker concentration.
- compositions that produce colored products upon interaction with a number of biomarkers are generally known, but will be briefly described herein below.
- a wide range of chemical compounds are known to absorb light, with the result that exposing a compound to a known spectrum and measuring light that absorbed and/or reflected at or near certain wavelengths can be used to identify the presence of particular compounds, and/or their concentration.
- the test reader 16 A is configured to employ photodiodes or other elements that emit light of particular wavelengths and/or intensity and photodetectors to measuring reflectance/absorbance to determine color and/or degree of color change.
- the resulting reflectance/absorbance measurements can be converted to determine a particular biomarkers concentration within a bodily fluid using a known calibration that may be stored on the reader 16 A, a computer 16 B or elsewhere.
- the test reader 16 A reads the unique sample and test panel ID 14 ( FIG. 2 ) from the test panel device 10 .
- the test reader 16 A may include various digital and analog components useful to perform the bodily fluid measurements, to read the unique ID 14 , and to create a resulting test data set.
- a plurality of light emitting and reflectance/absorbing measuring components may be spatially arranged to cooperate with the test panel device 10 and its arrangement of pads 12 and unique ID 14 ( FIG. 2 ) so that measurements may be taken from each pad 12 independently and unique ID 14 independently.
- the light emitting components direct a known spectrum of light toward the test panel device pads 12
- the reflectance/absorbing components measure the resultant reflectance and/or fluorescence.
- a difference between the emitted and light due to reflection or fluorescence can be measured in toto or over a specific portion of the electromagnetic spectrum and used to determine presence and concentration of particular biomarkers based on their reaction with specific reagents.
- test reader 16 and test panel device 10 may be configured in a cooperating manner so that the test panel device 10 is received in a particular and predictable orientation so that pads 12 and unique ID 14 are located in a known location upon insertion of the test panel device 10 in the test reader 16 .
- This can be accomplished in any number of manners, with examples including a mechanical arrangement featuring a cooperating slot or keyed arrangement, a motor driven loading tray that loads the test panel device 10 along a consistent path to a known location.
- a test reader 16 A may also be provided with a digital checking mechanism that includes one or more location markers on the test panel device 10 that are confirmed to be in their required locations before test reading was undertaken.
- the test reader 16 makes the plurality of bodily fluid biomarker measurements simultaneously for purposes of efficiency, speed of sample throughput and others.
- the measurements of different pads are not simultaneous, but done in series by a one or more scanners and other components that travel along the length of the test panel device 10 .
- test panel device 10 there can also be commercial advantages to including security information on the test panel device 10 .
- revenue will be received through sales of test panel devices 10 .
- a competitor will reverse engineer the test panel device 10 and sell competing products at a lower price that can be used with the test reader 16 .
- some embodiments of test panel device 10 include digital or other security information that acts as a “key” for use of the test reader 16 .
- test reader 16 initially examines the test panel device 10 searching for the presence of the security information before conducting a test. If the information is not present, no test is performed.
- the security information may be overt or covert, with some examples including a digital bar or other code (similar or identical to ID strip 14 ), a second digital or other code that in addition to ID strip 14 , an RFID chip (which may be on or embedded within the test panel device 10 ), and others.
- test reader 16 and test panel device 10 that utilize color change and cooperating optical measurement technology to measure biomarker concentration and/or presence.
- many other technologies will be useful in other embodiments. These may include, but are not limited to, illumination at a specified wavelength of light and, e.g. by employing band pass filters, measurement of only the light emitted at a different wavelength by fluorescence, measurement of the refraction of light as it passes through a chamber within the FTD 10 device, (e.g.
- the refraction of light may be used to determine the specific gravity to evaluate the relative concentration of a urine sample), the measurement of light emitted at a wavelength at which a specific chemical reaction used to quantify a biomarker does not exhibit any significant change in intensity with the biomarker concentration (known as the isobestic point) for purposes of internally calibrating the change in intensity at a second wavelength that is responsive to the concentration of the biomarker, control reaction pads that are sensitive to temperature and which can be used to detect exposure of the test panel device 10 to conditions that would damage its function, control chemical components in the test panel device 10 that may be used to quantify the relative amount of fluid that is taken up by the device and thus the amount of the sample being analyzed, control pads or channels that may be used to correct for endogenous absorption, reflection and/or fluorescence of light by the specimen (e.g. yellow or amber colors of urine or plasma specimens) and/or determination of the redox potential of a biofluid.
- control reaction pads that are sensitive to temperature and which can be used to detect exposure of the
- test reader 16 after performing bodily fluid measurements, with or without the separate input (manually or from remote data source) of additional biometric data on the individual being tested, creates a test data set.
- the test data set may include, for example, quantitative concentrations of biomarkers present in the bodily fluid measured by the test panel device 10 , normalized values after adjustment (e.g. based on creatinine or specific gravity values determined by the test panel device 10 ) in addition to a value corresponding to the unique ID 14 .
- the test data set may be in the form of a digital file that includes numerical values representing biomarker concentrations, identifying and biometric information on the individual tested and an alphanumeric string that corresponds to the unique ID 14 , for example, with one value corresponding to the concentration of each biomarker (and corresponding bodily fluid biochemical component) present in the bodily fluid sample 10 .
- bodily fluid measurements made in invention embodiments will vary with application. Again, in many embodiments, a plurality of measurements are made simultaneously from a single test panel device 10 . In some embodiments, bodily fluid measurements that measure concentration of biomarkers that correspond to oxidative stress, anti-oxidative activity, and inflammation are useful. A number of different such bodily fluid measurements will be useful in different invention embodiments, with examples including the following:
- Cytokines (TNF- ⁇ , IL-6, IL-8)
- an oxidative bodily fluid measurement can incorporate either a relatively specific method to quantify malondialdehyde (MDA) or 4-hydroxyonenal (4HNE) as biomarkers for lipid peroxidation and/or the less specific thiobarbituric acid reactive substances (TBARS) method to measure a broader range of substances oxidized to aldehydes and ketones due to the actions of free radicals.
- MDA malondialdehyde
- 4HNE 4-hydroxyonenal
- TBARS less specific thiobarbituric acid reactive substances
- Oxidative stress occurs when an abnormal level of reactive oxygen species (ROS), such as superoxide and/or hydroxyl ions, and/or hydrogen peroxide, lead to damage of molecules in the body.
- ROS reactive oxygen species
- ROS can be produced from fungal or viral infection, aging, UV radiation, pollution, excessive alcohol/tobacco consumption, drug metabolism, the uncoupling of electron transport systems in mitochondria, among other conditions.
- ROS can further cause many pathological conditions including age-related macular degeneration and cataracts, and is known to play a role in the development of multiple chronic illnesses including type 2 diabetes, cancers and cardiovascular diseases.
- Antioxidants help to control the level of ROS in the body and thus minimize oxidative damage to biomolecules and pathologies that may result.
- Tests have been developed to quantify many of the antioxidants that are produced by the human body. However, none of these have thus far been reduced to practice for the routine assessment of overall health and wellness.
- a number of complex tests have been developed to estimate the total level of all antioxidants in a specimen. Many of these tests, e.g. the ORAC test that is widely used to assess that antioxidant activity of foods and beverages, are intended for relatively sophisticated laboratories and involve the addition to a biological specimen of a dye that changes color upon oxidation, along with a source of ROS. In such tests, the higher the antioxidant activity of the specimen, the longer it takes for the dye to change color.
- Some embodiments of the invention utilize colorimetric tests for monitoring the antioxidant power of a biological sample due to multiple component antioxidants. These antioxidant power tests, sometimes called an antioxidant capacity tests, that employ copper-cuprione complexes (typically neocuprione or bathocuprione) or other complex that has a redox potential of approximately ⁇ 0.6.
- CUPRAC cupric reducing antioxidant capacity
- the CUPRAC method which employs a copper-neocuprione complex, for measuring the sum of the antioxidant activity due to multiple endogenous as well as exogenous (e.g. antioxidants derived from food and vitamin supplements) is particularly useful for providing as integrated value for an individual's ability to maintain a healthy response to ROS.
- further information may be included in the test data set. It may be useful in many embodiments that measure individual wellness data to collect various additional physical, personal and demographic data.
- demographic data is intended to broadly refer to data that may be useful to establish a related group. This might include, for example, demographic categories such as residence information, employer information, gender information, and other.
- additional information is provided by a test subject. This data may be manually provided through oral or written communications, or in another manner (with examples including scanning of an identity card such as a license/credit card, finger print scanning, retina scanning, and other). An operator can enter the information at the computer 16 B using a keyboard, mouse or other. In some embodiments, a credit card, license or other media with personal information can be scanned by the computer 16 B.
- personal, physical and demographic data that may be collected in invention embodiments includes but is not limited to demographic categories including:
- test reader 16 may also record a timestamp that corresponds to the time of measuring the bodily fluid test panel device 10 , and includes this timestamp with the test data set. The timestamp may be, for example, a day, month and year. It may be calculated using a clock internal to the test reader 16 , may be retrieved from the network 20 , may be manually input by an operator, or may otherwise be provided.
- some data may be modified or otherwise adjusted.
- a user social security number could include only the final four digits or some other portion, the date of birth may be limited to only a month and year (no day), residence information may be limited to city and state only (no street), user names may be partial or assigned pseudo-names, and the like.
- some advantage may be had in terms of security by not collecting and storing highly sensitive information such as a social security number.
- the data link 18 may be a wired or wireless link, with examples including a cellular phone communications link, a radio frequency connection, a PSTN communications link, a digital communications link, and the like.
- the network 20 may be any of a number of different communications networks, with examples including a wired or wireless phone network, PSTN, a digital network, a local area network, a wide area network, the internet, an internet successor such as the fast internet or next generation internet, a cellular communications network, combinations of one or more of these, and the like.
- the central computer 30 may be any number of processor based devices, with examples including a laptop, desktop, or server computer, a mainframe computer, and others.
- the computer 30 may include one or more memories (volatile and/or non-volatile), one or more displays, one or more data input devices (with examples including keyboards, mouse, microphone, others).
- the central computer 30 may be executing a program product of the invention, or a server incidence of a program product of the invention, and may have the same stored on a volatile or non-volatile memory.
- the central computer 30 has been illustrated as a single computer in FIG. 1 , it will be appreciated that in some embodiments the central computer 30 may include the functionality of a single computer spread across a plurality of computers. Indeed, current technology blurs the definition of computer, with many current devices including processors, memories and other components that are capable of executing stored instructions, storing data, and otherwise functioning as a computer.
- the central computer 30 serves important data processing, organizing, storing, and reporting functions.
- the central computer 30 stores in a memory, for example, average ranges for bodily fluid measurements that can be compared to the bodily fluid measurements from an individual test data set for calculation of a relative bodily fluid measurement.
- the reader 16 and/or computer 16 B may store these average values in a memory so that these calculations of relative measurements can be made without access to the central computer 30 .
- the term “relative” when used in this context refers to a measurement that is compared to a population range of the same measurements.
- a relative measurement may include a percentile or scaled or similar ranked measurement, with the result that an individual's bodily fluid measurements may be reported in comparison to a larger universe for context (e.g., “oxidative stress level is in the 35 th percentile,” or “oxidative stress is a 7.2 on a scale of 1 to 10,” etc.).
- the central computer uses this stored data and the test data set communicated from the test reader 16 to create a test output report.
- the test output report may be configured in any number of different forms as may be desirable. Indeed, as will be detailed below, one of the advantages of systems and methods of the invention is the ability to create highly customized test output reports to serve different needs. In many embodiments, however, the test output report will include a plurality of relative bodily fluid measurements in addition to some personal and demographic information.
- FIG. 3 illustrates one example test output report.
- the example test output report presents relative biomarker measurement results in a graphical format for convenience of consideration.
- Biomarker measurements that quantify oxidative damage are summarized by providing a numerical index for oxidative damage on a color coded line graph, with one end of the line and one color representing the lowest numerical value and corresponding best result, and the distal end of the line having a different (and often “opposite” with red and green being an example) color and representing the highest numerical value and corresponding worst result.
- This is a useful feature of some invention embodiments, using color to indicate results.
- Textual indicators may also be provided (e.g., “low, medium, high” or “reduced, elevated, highly elevated”, etc.)
- test output reports that present biomarker measurement results in this relative form are more easily understood and are more likely to have an impact on individuals.
- individuals appreciate health test results favorably through use of color coding which can include, for example, green for healthy readings, yellow for less healthy measurements, and red for most unhealthy measurements, with gradual color shading used to transition from one to the other.
- some invention embodiments are directed to measuring an individual's so-called wellness (generally recognized as including metrics such as physical activity, body mass and lifestyle that are healthy and/or low levels of biomarkers that are indicative of risk for chronic illnesses), as opposed to diagnosis of a particular disease or ailment. These embodiments make measurements of biomarkers in body fluids useful to generally assess an individual's capacity to resist general classes of disease and ailments.
- a test output report that includes a plurality of relative biomarker measurements in body fluids including the following has been discovered to be particularly useful: oxidative stress or damage (e.g. bodily fluid measurements of the biomarkers TBARS and MDS), inflammation (e.g. bodily fluid measurements of urinary protein and for NO x ), and total antioxidant capacity (e.g. relative bodily fluid measurements of TAC).
- oxidative stress or damage e.g. bodily fluid measurements of the biomarkers TBARS and MDS
- inflammation e.g. bodily fluid measurements of urinary protein and for NO x
- total antioxidant capacity e.g. relative bodily fluid measurements of TAC
- a test output report may include other results with one example including a body mass index (BMI) that is calculated based on input of an individual's height and weight. Other data such as age, ankle and/or wrist diameter, waist and chest diameter, may also be useful to assess wellness relative to one's peers. Some or all of the personal and demographic data may also be provided.
- the demographic data may also be used in formulating a test output report and/or test output data.
- Demographic data may be used in combination with numerical results to further estimate some aspects of a subject's wellness and disease risk and to provide information on the test output report. For example, demographic data indicating that a subject is a heavy smoker or heavy user of alcohol and that has an elevated level of a biomarker(s) for oxidative stress might be useful to provide a recommendation for lessening the oxidative stress level. At least some literature supports the proposition that smoking cessation reduces oxidative stress using one biomarker.
- Test output reports may be communicated as desired. Individuals that submitted a bodily fluid sample will be one destination for test output reports. These individuals may be mailed (by physical or electronic mail) a test output report. The test output report may be communicated over the communications network 20 to a computer 16 B for printing on an attached printer (not illustrated), viewing on a display, or for storing in a memory for future use. Also, an advantage of many invention embodiments is that the test output reports are stored in a memory by the central computer 30 for presentation as desired. An individual may be provided access to the central computer 30 over the data network 20 (or otherwise) so that they can retrieve their test output report as desired whenever and wherever they may be.
- test output report communication and storage may be encrypted. Storage and communication may utilize other high security measures to avoid data breach.
- FIG. 1 shows a mobile communications device 34 that may be a cellular phone, a radio phone, a radio, a smart phone, a gaming or entertainment device or other mobile processor based device that is in communication with the network 20 .
- An individual may use this mobile communications device 34 to communicate a request over the network 20 to the central computer 30 for a test output report.
- the central computer 30 may respond to this request by communicating the corresponding test output report to the communications device 34 , which may display it on a local display, communicate it to another device (monitor or printer or other) for display or output, and/or store it in a memory for future use.
- the central computer In order to associate an individual with their corresponding bodily fluid test data set and/or a corresponding test output report, the central computer necessarily must be able to identify the stored data with the individual referenced in the request it has received. There are a number of particular steps that can be undertaken to achieve this, but most have in common that some information included in the request can be used to identify the stored data. This may be, for example, personal data such as an individual's name, social security number, address or the like. Also, in many invention embodiments, the test reader 16 and central computer 30 are configured to provide and recognize a unique security key that is associated with an individual. As used herein, the term “security key” is intended to broadly refer to a unique identifier that may be communicated digitally. It can be, for example, an alphanumeric string such as a password.
- the test reader 16 is configured to provide the security key to the individual before the test data set is communicated to the central computer 30 , while in other embodiments a request is communicated to the central computer to create a security key which is then communicated to the test reader 16 before the test data set is communicated to the central computer 30 .
- the initial test data set may be communicated to the central computer 30 which then creates a corresponding security key and communicates it to the test reader 16 . Individuals may also be permitted to create a desired security key for convenience.
- more than one security key is provided.
- an individual may be asked to create a username and password (each of which may be a security keys in the context of the invention).
- the central computer may confirm that the user name and password are available for use through a dialogue, and then assign these to the individual as well as corresponding test data sets and test output reports.
- data used in various invention embodiments may include sensitive personal information, including identification and health related data.
- Some invention embodiments may include numerous features to ensure a high level of data communication, storage and reporting security. This may include, for example, multiple security keys, data encryption, highly reliable storage procedures, and the like.
- Data communicated to and from central computer 30 including but not limited to test data sets and test output reports, may be encrypted.
- encryption may include installation of a client codec on client devices, sharing of a digital encryption key between client and server, and the like.
- test data sets and test output reports may also be useful for one or more others to have access to test data sets and test output reports in addition to the individual that submitted the bodily fluid test sample.
- Health care professionals that care for the individual, relatives, employers, insurers and others are some examples of others that may find utility in accessing stored test data sets and/or stored test output reports.
- the individual can provide his security key to others as he desires so that they can access stored data.
- the test reader 16 and/or the central computer 30 are configured to provide one or more additional security keys.
- different security keys may carry different levels of access, with a first security key allowing access to all stored data, a second security key providing access to only a limited subset of the stored data, a third security key providing access to a still further limited data set, etc.
- test data sets, test output reports and other data may be any number of individuals that are related to one another in some manner.
- an employer may contract to administer testing to all of its employees.
- the employer may wish to have access to the test output reports for all of its employees.
- the central computer may provide a security key to the employer that is common to all employees.
- the different security keys may have different levels of access so that a first security key can access more stored data than a second key. This can be useful, for example, so that an employer can access some but not all stored data for its employees, while employees can access all information.
- the central computer 30 of invention embodiments provides unique benefits and advantages through novel data processing, organizing, segmenting, storing, and output features. Some of these features correspond to organizing test data sets into groups. Organizing data into groups may be useful for a variety of different purposes. Groups can be created using data stored by the central computer, or can be defined when submitting data. As an example, in some embodiments a group could be created using demographic data for all women between the ages of 30-35, for all individuals that reside in a particular geographic location (e.g., city, state, county, zip code(s), etc.), all individuals of a certain vocation, and any number of other selections using existing, stored data. In still other embodiments, a group can be created upon submission of initial test data sets. As an example, a test reader 16 operator may input data confirming that a data set to be created by the reader is part of a group. A plurality of corresponding test data sets may include a common group identifier, which may be an assigned alphanumeric string.
- FIG. 4 illustrates a general chart, it will be appreciated that this is an example only and is provided as one example illustration of data that can be stored and organized by systems, methods and program products of the invention.
- the data may be manipulated within the configuration of a relational database.
- individual test data sets are organized as rows and categories of data organized by columns. This is a somewhat simple example for purposes of illustration, and it will be appreciated that some actual test data sets will include far more data.
- each example test data set includes an individual name, a username (representing a first security key), two additional security keys, a birthdate (DOB), a test date (date the test was given), residence, race (coded), group, gender, tobacco use profile (expressed in a code corresponding to severity of use), education (expressed in number of years), vocation (coded), body mass index (BMI—expressed in a code), and normalized (and/or un-normalized or raw) bodily fluid measurement values for five different biomarkers (BM 1 -BM 5 ).
- This information can be organized as desired, and may be grouped as has been illustrated in FIG.
- “personal data” including DOB, race and gender (columns A-D); security information including three different security keys (columns E-G); other personal data including a group identifier for first and second groups (if any), residence address, tobacco use profile, education level, and vocation (columns H-M); actual test data including a test date and five individual bodily fluid measurements (organized as biomarker measurements or BM) (columns N-T), and a test ID (corresponding to data from ID strip 14 which may be a unique test identifier).
- FIG. 4 is an example only, and that in practice test data sets may include more, less, or different data, and may be organized in different manners.
- FIG. 4 shows BMI or body mass index.
- body mass index can be routinely calculated using weight and height.
- Body fat percentage estimation, and similar additional metrics, for example, can sometimes also depend on age, waist, chest, wrist, ankle and other measurements.
- the underlying data is included in the test data set and stored by the central computer 30 in a memory. In other embodiments, however, the underlying data is provided by a user, but the resulting calculation is performed and only that resulting value stored (as opposed to the underlying data). Also, in some embodiments these calculations are performed by computer 16 B with only the resulting calculated value communicated to the central computer 30 , while in other embodiments the underlying data is communicated to the central computer and the calculations made by the central computer 30 .
- the test output report can be generated (including making of all required calculations as described above) can be performed by the local computer 16 B.
- the local computer can store, for example, in a memory all of the data required to generate normalized or relative measurement data. This can be advantageous, for example, in applications in which a network 18 is not available and for other reasons.
- encryption of the data report may be used in some embodiments for security purposes when it is stored and/or communicated over the network 20 .
- a company named “Acme” desires to estimate the overall wellness of its employees. Further assume that Acme has a facility in Chicago and one in Milwaukee. This information may be input by one or more operators using a computer 16 B, central computer 30 or other device over network 20 . Central computer 30 responds by creating a first group for Acme (indicated by “acme” in FIG. 4 , col. H) and a subgroup for each of the Chicago and Milwaukee facilities (indicated by “Chi” and “Mil” in FIG. 4 col. I).
- An operator, a computer 16 B, or the central computer 30 further creates a security key for Acme—“acmeJ23.”
- This security key may be communicated to an Acme manager or other representative of Acme to facilitate their access to stored test data sets and/or stored test output reports for Acme employees that will be created.
- a plurality of employees at each of the Acme Chicago and Milwaukee facilities are then tested. Each employee provides a bodily fluid sample which may be urine. A different test panel device 10 is exposed to each urine sample. Permanent personal data ( FIG. 4 , col. A-D) and other personal data (Col. H-M) is collected for each individual employee Individual and associated with the corresponding test panel device 10 ( FIG. 2 ). This can be accomplished, for example, by individual employees providing a paper form that is provided with their urine sample, by computer 16 B retrieving the data from an Acme database accessible over computer network 20 (not illustrated), by an individual employee or other operator entering the data in response to queries or through a provided form on computer 16 B or other computer accessible to network 20 , or through other appropriate steps.
- test panel device 10 for each Acme employee are then read by a first test reader 16 that is temporarily located at the Acme Chicago facility and by a second test reader 16 that is temporarily at the Acme Milwaukee facility.
- Individual test data sets are created for each individual employee including the data as indicated in FIG. 4 .
- a username and password are created for each employee, either by computer 16 B or by central computer 30 .
- This may be accomplished, for example, by computer 16 B requesting creation of a new individual account from central computer 30 which responds by providing a unique username and password to computer 16 B.
- An individual account may be thought of as a user identity that will be associated with one or more test data records.
- Computer 16 B may have also included in its request to central computer 30 that the new account would be associated with the Acme group as well as the appropriate subgroup.
- central computer 30 may have been informed of the total number of employees to be tested at each facility (and in some embodiments their names) and created a corresponding number of new accounts.
- Each individual test panel device 10 is then read by reader 16 A to make individual biomarker measurements BM 1 -BM 5 .
- the body mass index may be calculated by computer 16 B (or may be calculated by central computer 30 ).
- An individual report may be created by the computer 16 B and, along with the test data record communicated from computer 16 B over the links 18 and network 20 to central computer 30 .
- Central computer 30 stores the data records in a memory using the general organization as shown in FIG. 4 .
- the test data sets shown in rows 1 - 5 are stored, with those of rows 1 - 3 corresponding to Acme employees at the Chicago facility and rows 4 - 5 Acme employees at the Milwaukee facility.
- FIG. 4 that includes 5 Acme employee individual test data records represents an abbreviated example only, and that in practice tens, hundreds, thousands or more of test data records may be stored.
- FIG. 4 illustrates test data sets for two individuals that are associated with the AARP group (rows 6 - 7 ), and a test data set for an individual that is not associated with any group (row 8 for Hank Right).
- the AARP test data sets do not have a second group identifier (no entry in column I). This indicates that for the AARP group no sub-groups have been set up.
- the Hank Right test data set in row 8 has no group association, which might result if Mr. Right, for example, submitted a bodily fluid sample for testing at his physician's office, at a pharmacy, or other location as an individual.
- the final row of FIG. 4 (row 9 ) is a second test data set for Joe Smith, one of the Acme employees.
- This test data set is not associated with the Acme group, which could result if Mr. Smith submitted a second bodily fluid sample for testing at another time/location from the Acme business testing.
- the security data for this test data set overlaps with that of the earlier Smith test data set (shown in row 1 ), except that there is no security key 3 associated with it (no entry in column G).
- the username (security key 1 ) and security key 2 are the same as for the first Smith test (row 1 ). This might result if when submitting his second bodily fluid test sample, Mr. Smith submitted his existing username and security key 2 . This may be done, for example, by Mr.
- Mr. Smith filling out a paper form that is read by a test reader 16 , by Mr. Smith entering the username and security key directly into test reader 16 using a keyboard, microphone or other data input device, by Mr. Smith providing an identity card or other data carrying device that is read by a test reader 16 , or in other steps.
- the computer 16 B or central computer 30 may respond by providing Mr. Smith's permanent personal data (columns A-D) from Mr. Smith's prior test that is constant. This data may be directly populated into the second test data set for convenience so that Mr. Smith need not be required to present it a second time.
- the request received from Mr. Smith might specify particular desired report characteristics. These might be, for example, a request for a test output report including only relative data for BM 1 and BM 2 .
- the data of FIG. 4 indicate that three different test data sets exist for Mr. Smith, each taken at a different time.
- the request for a test output report submitted by Mr. Smith may specify which of the different test data sets to use to create the desired test output report.
- the request might specify that the test output report should include relative results calculated over time using multiple test data sets.
- Mr. Smith's example it might be useful for him to have a test output report that showed changes in relative biomarker measurements over time. This can be useful, for example, to measure changes in his biomarker levels over time as Mr. Smith attempts to modify his lifestyle (through changes in diet, exercise, or other), or conversely a decline in wellness due to age and no lifestyle changes.
- a group such as Acme could request to view results for its group as they change over time. Aggregate data for Acme employees may also prove useful for Acme to obtain lower rates for coverage.
- FIG. 5 illustrates one example set of steps for generating a test output report which may be embodied in a method or program product embodiment of the invention, or performed by a system of the invention.
- FIG. 5 it will be appreciated that various elements of FIG. 1 (and in particular the central computer 30 ) and data of FIG. 4 will be referenced. Element numbers of these FIGS. will be understood to refer to those FIGS.
- the central computer 30 first receives a request for a test output report from the network 20 (block 52 ).
- the request may be communicated from an individual such as Mr. Smith, an employer such as Acme, a health care provider representing an individual, or from another source. It can be communicated using any device in communication with the network 20 , including computer 16 B, smart phone 34 , or other device.
- the central computer queries the request to identify what individual(s) a test output report is desired for (block 54 ). This step also includes the central computer confirming that that request has presented sufficient security key(s) to access the requested data (block 54 ). If the proper security keys are not provided, an error message results (block 58 ) and no data is provided. If a request includes proper security keys, the process of collecting and organizing data continues (block 60 ).
- a request may have been received for an output report that specifies the name “Hank Right” or otherwise specifies Mr. Right as shown in row 8 of FIG. 4 .
- the request In order for the central computer to proceed, the request must necessarily identify Mr. Right and include one or more of the required security keys shown in columns E-G of FIG. 4 .
- some invention embodiments allow for different levels of data access to be provided with different security keys.
- a first request that specifies a test output report based on Mr. Right's data could include the username “Left 1 ” and second security key 899925 shown in columns E and F.
- the central computer may recognize the inclusion of these two security keys as a signal to allow full access to the Mr. Right's data included in row 8 .
- This username and second security key may have been provided, for instance, to Mr. Right, with the understanding that he would use these to retrieve his test data when desired.
- a different request received by the central computer that specifies Mr. Smith may include the third security key shown in col. G of FIG. 4 (Q 88 P), but not the first or second security keys.
- the central computer when executing block 56 will recognize this as a signal to provide only limited access to the data.
- the access may be limited to only the test data of columns N-S but no other data from row 8 .
- limited access may allow for test data of columns N-S as well as selected (but not all) other personal data and permanent personal data. Many variations may be practiced as desired.
- test output reports are highly customizable and corresponding requests for an output report may specify details of what is desired on the test output report.
- the input of such detail may be provided through an on-line menu on a processor based device in communication with the network 20 (with examples including computer 16 B and portable device 34 ), through paper forms, or through other means.
- one or more standard output reports may be offered that provide pre-selected relative bodily fluid measurements. Examples of particular output reports will be provided below through further illustration of various invention embodiments, with one such example report illustrated in FIG. 3 and discussed above.
- the central computer 30 retrieves required data from the corresponding test data record(s) (block 62 ). Again, the required data will vary depending on details of the desired output report. Many requests will require retrieval of only a single test data set, while others may require retrieval of a plurality. As also discussed above, many embodiments feature output reports that provide relative data. This has been discovered to offer unique benefits and advantages as discussed above. To provide relative data, an individual test data set is compared to a larger universe of data to provide further context. A wide variety of universes may be selected and will be determined by the central computer through specifications in the request (block 64 ).
- the central computer 30 may store the universe data in a memory (local or accessible over network 20 ). Taking the BMI data from FIG. 4 as an example, the central computer 30 may store a universe for BMI data that includes a mean, median, standard deviation(s), maximum, minimum and other statistical averages from across tens of thousands of samples that shows an expected range of from 18 to 30, with a mean of 23.2 and median of 23.7.
- the universe data may be segmented as desired according to demographic categories, with examples being universe data presented by gender, age, occupation, residence, or any other desired demographic category. Universe data may be obtained from literature or other sources.
- advantages and benefits are achieved by configuring the central computer 30 to develop universe data as desired using stored test data sets, as reflected in block 64 .
- Development of universe data is further customizable in invention embodiments as may be desired. It has been discovered, for example, that great utility can be achieved by allowing users to define their own universe. As an example, the Acme employer or an individual Acme employee may wish to view the results of his biomarker measurements relative to the universe of all Acme employees. In this case, test output reports for an individual could be prepared which compared that individual's BM 1 measurement to the overall universe of BM 1 measurements of all members of the Acme group.
- the central computer 30 accomplishes this by retrieving all records specifying the Acme group identifier in column H of the table of FIG. 4 . Or, the particular employee may wish to compare their results to only female Acme employees that use tobacco, are married, are accountants, and live in Chicago. Again, the central computer 30 could accomplish this by selecting corresponding records from the table of FIG. 4 . Although this universe may appear somewhat arbitrary, it is useful to illustrate the capabilities of invention embodiments in developing a desired universe across a great variety of potential variables that may be useful for one or another reason. A number of universes may be developed using any number of different stored demographic and personal data. The central computer 30 may facilitate selection of the desired universe through presentation of menus or other graphical selection criteria to a user over the network 20 .
- the output report may include relative bodily fluid measurements as desired and specified by a user, with an example shown in FIG. 3 .
- advantages and benefits are gained by providing a plurality of biomarker measurements.
- Relative biomarker measurements may be presented in a graphical form as discussed above and illustrated in FIG. 3 , any may include a color grading to aid comprehension. Additional information may be presented in the output report, including but not limited personal information, group information, or other.
- the assembled output report is then communicated over the network 20 for storage, display, printing or other use at a remote device such as computer 16 B, portable device 34 , or the like (block 66 ).
- availability of various output reports will also vary with level of security key access.
- a representative of the Acme employer may wish to view overall results for the universe of Acme employees, or a selected sub-group such as the Acme Milwaukee facility, male employees between the ages of 30 and 35, or other.
- the Acme representative may have been provided only the security key “AcmeJ23” shown in column G of FIG. 4 .
- Presentation of this security key in the request communicated to the central computer 30 may allow for access to only limited portions of the test data sets for the Acme employees, with an example being the test data ( FIG. 4 , columns N-S) but no, or in some embodiments a limited set, of personal and permanent personal data. This may be useful to protect some portions of personal data.
- presentation of a particular group level security key such as the AcmeJ23 of column G will provide access only to statistical values representing the overall group data but not any single test data set. So, by way of illustration, in some embodiments presentation of the AcmeJ23 security key serves as a signal for the central computer to include on a test output report only the average, range, mean, median and other statistical values for the Acme group, but not any individual biomarker measurement data.
- Test output reports may also present biomarker measurement data taken over time. Again, it has been discovered that this allows for benefits and advantages related to individuals and groups being able to measure changes over time as behavior, diet, and other factors change.
- a request processed by the central computer may specify, for example, that a particular user desires to have all their bodily fluid measurements charted over time, either in raw (i.e., not relative) form or in relative form. This could be accomplished, for example, by a user specifying some or all of their permanent personal data, security key information, or other data that is associated with each of their test data sets, and the central computer 30 then using this to search a memory or database and identity every test data set that corresponds to that user. Referring to FIG. 4 by way of example, Joe R. Smith has two test data sets (rows 1 and 9 ) which each have common first and second security key information as well as permanent personal data.
- the unique data gathering, storing and reporting capabilities of invention embodiments can be exploited in a number of other ways to offer other valuable benefits and advantages not previously available.
- the data stored by invention embodiments can serve as the basis for predictions of future events.
- correlations can be utilized to predict future rates of incidents of various diseases, health care costs, and the like for groups or individuals.
- a correlation could be referenced, for example, that associates the average BM 1 , BM 2 , BM 3 and BM 4 for the Acme employer to predicted health care costs for the coming years.
- Acme might provide access to its security key 3 to an actuary or other entity that could review data and make such predictions.
- Embodiments of the invention also include developing such correlations.
- Acme and other employers could provide their health care costs by year, for example, which can then be compared to average bodily fluid measurement data to create a health care cost correlation.
- Such predictive data will find utility in a multitude of applications.
- One example includes actuarial applications for insurance companies.
- An insurance company providing insurance cost estimates or determining annual premiums for the Acme company, for instance, could find great use in having all Acme employee test data records and applying a correlation factor to their average measurements to predict future health care costs.
- comparisons of different groups' statistical data values can be made for predictive purposes or other purposes.
- a central computer 30 of the invention stores test data sets for 17 different Acme facilities, each located remotely from the other. If Acme is considering closing one facility, expanding one facility, it could find utility in comparing statistical data for each different facility to identify those that may have particularly high or particularly low relative bodily fluid measurement data (e.g., particularly healthy or unhealthy facilities). Doing so may be useful to predict expected relative health care costs which can aid decision making. Similarly, Acme may wish to identify which of its 17 facilities has the healthiest workforce so that other facilities can model operations on that facility.
- Still other embodiments include further features of analyzing data sets. As the system acquires new data sets, multiple data analysis and cultivation opportunities are presented. Indeed, an important advantage of some invention embodiments lies in their scalability. As the volume of data collected grows, the value of statistical and other information to be gained from the data grows. Analysis of accumulated data is not limited to averages for populations or groups. As an example, as data sets are added, some embodiments further interrogate and identify subgroups at a highly granular level. Such identification can be useful to achieve further predictive usefulness.
- an illustrative example includes identifying a subgroup based on a behavioral change.
- Data sets for users that stop smoking, begin exercising, or have other behavior change(s) may be useful to offer guidance for others considering the same change as to how data will change in the future and otherwise what to anticipate in the future. Changes other than behavior can be used as well, with examples including loss of a specified amount of weight, geographic moves, employment changes, and others.
- analysis may be performed from a results perspective going backward to identify subgroups. As an example, some embodiments may employ statistical analysis to identify common traits among users that have reported some measureable change in one or more biomarkers or other data (e.g., a weight loss of 10% or more). Some subgroup may be identified through such analysis that share some common trait(s).
- a further security key(s) may be provided to access multiple different groups for comparison sake by a third party.
- the data of FIG. 4 includes group data for a multitude of other companies.
- An insurance company that is quoting insurance to two of those companies may find utility in accessing the overall statistical values for each company to compare them to one another and determine which should be quoted a higher insurance cost.
- a third company is considering acquiring Acme or one of its competitors, it may find value in accessing the overall statistical values for each company to compare them to one another and determine which is likely to have higher health care costs in the future.
- the central computer may receive, associate with a user and store in a database such as that illustrated in FIG. 4 further data.
- An individual may upon providing sufficient security information (such as one or more security keys) communicate weight, blood pressure and date data to the central computer 30 so that this data is associated with the user's already stored data.
- the data stored by the central computer may include other data in addition to data sets generated by test readers 16 , and may include other data directly input by users at a later time.
- the central computer 30 may output any selected data in a graphical or other form.
- a user could, for instance, obtain a chart that plots their weight and other data over time. From a commercial standpoint, these central computer capabilities of allowing users to input and to store and output other data in addition to data sets from test reader 16 may provide significant commercial advantages. It may create additional reasons for users to access the central computer 30 which leads to higher traffic and therefore greater opportunities for advertising or other revenue.
- advertising revenue is collected based on targeted advertising to users as they access data or otherwise interact with central computer 30 .
- Some system, method, and program product embodiments of the invention provide targeted advertising over the network 20 .
- the term “targeted advertisement” is intended to broadly refer to selecting particular advertisements for specific users based on some data for that user, as opposed to using the same advertisement for all users.
- the advertising is targeted based on some defined criteria using data stored by the central computer 30 related to particular users.
- the targeted ads may be determined based on test data sets, demographic data, or other data.
- users that indicate they are high frequency exercisers may be targeted for exercise equipment advertising
- users that are identified as having lost a significant amount of weight may be targeted for clothing advertisements (since they may need new clothing)
- users that indicate they are heavy alcohol users may be targeted for alcohol ads (or substance abuse treatment ads)
- suggestions for birthday dinners may be provided to a user in advance of a user birthday, and the like.
- Advertisements may appear as pop-up or other visual content on a screen connected to the network 20 , may be in the form of telephone calls, e-mail instant or other electronic communications, paper mail, or other.
- test readers 16 include automated communication of test readers 16 over the network 20 . This can be useful to update software running on test readers 16 , to diagnose test readers 16 that require maintenance, to automatically track status of test readers 16 , and for other purposes. In most embodiments, test readers 16 require execution of some stored program code. Such code will be updated from time to time, with different versions being identified using different version numbers. Likewise, test readers 16 may require periodic maintenance to check and/or repair operation of various components. In some invention embodiments, test readers 16 are configured to communicate over the network 20 with central computer 30 or other computer to address these tasks in an automated manner.
- test readers 16 are configured to communicate over the network 20 with the central computer 30 or other computer on some regular interval to perform routine diagnostics.
- the diagnostics may check operation of various test reader 16 components and operation, and may identify test readers 16 or its components for repair.
- the interval may be selected as desired, with examples including every time the test reader 16 connects to the network 20 , once a week, once a month, once quarterly, and once annually.
- test readers are configured to communicate over the network 20 with the central computer 30 or other computer on some regular interval to check for operating software updates.
- the test reader 16 may compare the version number of its operating software with that of the most currently available version available over the network 20 , and if a more recent version is available it may automatically download the update. Again, the interval may be selected as desired, with examples including every time the test reader 16 connects to the network 20 , once a week, once a month, once quarterly, and once annually.
- test readers 16 are configured to store data necessary to provide test output reports without accessing the central computer 30 .
- test readers will store universe data on a local memory so that relative output data can be calculated. This universe data may be updated from time to time. In some embodiments, such updates are done automatically on a desired interval over the network 20 .
- the test reader may communicate with the central computer 30 or other computer over the network 20 to determine if updated universe data is available. If it is, the test reader 16 may download it.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
- Fields of the invention include systems, methods and program products for collecting, and organizing health data. Another field is wellness data determination.
- Health of individuals is important for obvious reasons. Individuals often seek medical advice for diagnosis of disease and as an aid in the evaluation of an individual's overall health and wellness (e.g. as part of a periodic check-up). Unfortunately, consultation with medical professionals often has an economic cost associated with it that limits access for many.
- The understanding of the science of health continues to increase. It is now possible to perform certain biochemical measurements on an individual's body fluid(s) and use the results as an indicator of risk for becoming afflicted with a variety of different ailments (e.g. cholesterol and lipoprotein analyses on blood samples). Due to the costs of seeking professional medical advice, the cost of the analyses themselves, in addition to other problems in the art, however, corresponding advances in the science of health and disease risk assessment have not been fully utilized.
- One example embodiment of the invention is a system for collecting, measuring and outputting health data. The system comprises a plurality of test readers that each determine a plurality of different bodily fluid measurements in a bodily fluid sample and that generate a test data set for each bodily fluid sample that comprises the plurality of different biomarker measurements and communicate the test data sets over a network. A central computer is linked to each of the plurality of test readers over the network and receives the test data set and stores the test data sets in a memory, the central computer associating at least a first security key with the test data set. The central computer responds to a first request for a test output report received over a network that includes the first security key by communicating a test output report that includes a plurality of bodily fluid test measurements and transmits it over the network.
- Another example embodiment comprises a computer program product comprising executable instructions stored in a non-volatile non-transitory memory (with examples including but not limited to magnetic, chemical and optical memory media), the instructions when executed causing one or more computers to execute steps comprising: receive a plurality of individual test data sets over a network from test readers that are connected to the network, each of the plurality of test data sets generated from a bodily fluid sample taken from an individual and including bodily fluid measurement data for at least three different biomarkers that are useful to estimate oxidative damage, antioxidant capacity, and inflammatory status; store the plurality of data sets in a memory; associate a plurality of the test data sets with a first security key that corresponds to a related group in the memory; receive over a network a first request for a group output report, the request including the first security key; use the first security key to identify from the memory the plurality of test data sets that correspond to the group; calculate averages for each of the bodily fluid measurements from all of the test data sets that correspond to the group; and prepare a group output report that includes the bodily fluid measurement averages for the group and communicate the group output report over the network.
-
FIG. 1 is a schematic that is useful to illustrate some invention embodiments; -
FIG. 2 is a schematic illustration of a bodily fluid test panel device of a system of the invention; -
FIG. 3 is a representation of a sample test output report of an invention embodiment; -
FIG. 4 is a representation of sample data stored by an invention embodiment; -
FIG. 5 is a flowchart illustrating steps performed by an example system or program product of the invention. - Before describing example embodiments of the invention, it will be appreciated that the invention may be embodied in one or more of a system, method, software, or program product. Accordingly, it will be appreciated that in describing one example embodiment of the invention, description of other embodiments may likewise be had. As an example, when describing a system of the invention, description of a method, software or program product may also be had. Additionally, a method of the invention may be carried out by a system of the invention, and a program product of the invention may be stored on one or more non-volatile memories linked to a system of the invention that when executed cause the system to carry out a method of the invention.
- Example systems, methods and program products of the invention are directed to collecting, storing, processing, and outputting health data. As an example, a system can be provided for collecting, storing, processing and outputting data obtained from measurements performed on bodily fluid samples from individuals, with or without additional information on the individual (such as height, weight, age, gender, lifestyle and health history data that may be input manually or electronically populated and is incorporated into the complete record for a specific test) in a highly efficient manner to provide a useful indication of the individual's overall health, wellness and/or relative risk for contracting one or more illnesses. The bodily fluid sample is contained in a test sample holder, which may contain discrete components for the measurement of multiple substances in bodily fluids for convenience and to reduce time and expense. Resulting test data is measured by a device which may be comprised of a single physical unit or multiple separate components for the measurement of biomarker(s) and for the control of certain aspects of the function of the measurement component and for computation of the results, processing of an on-site report, and transmission of data to a central computer, stored, processed by a central computer. Resultant test reports can be provided to individuals and others in a variety of useful and customizable formats. In some embodiments test results are stored over time so that individuals and others can measure changes in the levels of biomarkers and other metrics of health and wellness over time. In some embodiments, the tests and results are particularly well suited for estimating an individual's overall wellness, which may be thought of as health and/or resistance to one or more chronic diseases.
- In further embodiments, pluralities or even multiplicities of individuals that are related to one another to form a group can have their test data organized, analyzed, and otherwise treated as a group. This provides some powerful and useful advantages and benefits over the prior art. One example group is a selected general demographic category(s) (any combination of age, geographic location, gender, lifestyle profiles), another may be employees of a particular employer or students from a particular school, and others are combinations of these (e.g., all women between ages of 35-40 that are employees of a particular company). Such groups can obtain an overall health profile for their members, map it over time, compare individuals or group averages to other selected groups or universes, and in some embodiments make predictive projections of health care costs, incidences of particular diseases and other predictions.
- Description of particular example embodiments may now be had, with reference drawn to
FIG. 1 . A bodily fluid sample is held by a test sample holder, with one example beingtest panel device 10 test panel device may include urine, feces, blood, saliva or other bodily fluid sample, or some residue thereof, and may include a DNA sample. In many embodiments, the bodily fluidtest panel device 10 includes (or is) a dip stick cartridge that supports, contains or otherwise holds one or more urine dip sticks having multiple discretely arranged testing channels or test pads, each of which is embedded with reagents that react with different biochemical components in the bodily fluid sample such as urine. In addition to a dip stick, other test panel devicetest panel device 10 configurations include (but are not limited to) a microfluidic or a lateral flow immunoassay device and the like. When testing bodily fluids other than urine (with examples including saliva and blood), other configurations may be desirable. - Although other bodily fluids may be utilized in invention embodiments, it has been discovered that many embodiments find significant utility through use of urine. Urine offers advantages in many embodiments since its collection is relatively easy and noninvasive, collection and handling poses minimal infectious disease risk to participants and operators of the testing system and since urine provides sufficient volume for multiple assays. Urine specimens are well suited for large studies because they can be collected and stored by participants, costs of collection are relatively low, and compliance is high.
- A test subject such as a person (not illustrated) may provide a urine sample that is communicated to the bodily
fluid test device 10 through immersion, dropwise addition, capillary flow, or other manner. In some embodiments the bodilyfluid test device 10 includes a plurality of reagents that react with a plurality of different biochemical components of urine. The term biomarker as used herein broadly refers to a substance or group of substances in a biological sample that is (are) associated with a specific disease or condition, with an example being glucose in urine being associated with a hyperglycemic condition of a diabetic individual. The product of the reaction of a given biomarker with reagents, chemicals or antibodies in a specific pad or channel of the test panel devicetest panel device 10 may result in a color or other detectable change, which detectable change that can be detected and preferably quantified by thereader device 16A. In some embodiments, a bodily fluidtest panel device 10 may be comprised of test pads or channels that discretely measure the levels of two biomarkers, in others three biomarkers, others four biomarkers, others five biomarkers, others six biomarkers, others seven biomarkers, and others additional numbers of biomarkers. Including a plurality of different biomarkers on a single bodilyfluid test device 10 provides advantages related to efficiency of time, cost, effort and others. - The bodily fluid
test panel device 10 may be provided in any number of different mechanical, chemical and/or immunochemical configurations in different invention embodiments. As indicated above, in some embodiments it may include a polymer cartridge containing a urine dipstick. Many aspects of the science of bodily fluid testing, with urine testing being one example, are generally well understood by those knowledgeable in the art and these aspects need not be detailed herein and will not be for sake of brevity. A brief summary of relevant aspects, however, is provided for completeness. - Many (but not all) embodiments of the
test panel device 10 use dry chemistry technology. A dry chemical media is provided and attached, held by, supported by or otherwise contained in or on a plastic frame or holder. The dry chemical media may include a dry carrier such as paper, powder (which may be compressed into a solid), pad, gel, glass or plastic fiber or other media that is loaded, embedded, impregnated or otherwise carries one or more reagents which, when exposed to a bodily fluid such as urine, will react to produce a detectable (and in many embodiments a quantitatively measurable) change in physical property. In some embodiments, the reaction product results in a color change. Other examples of physical changes include fluorescence and a change in redox potential. - Again, when practicing an invention embodiment that is directed to testing of urine, urine dipstick technology may be utilized with the dry dipstick media carried in a polymer case for convenience, hygiene, security and other reasons. As further indicated above, in many invention embodiments the bodily
fluid test device 10 provides for convenient testing of a plurality of different biomarkers in a single test. Accordingly, sometest panel device 10 include different reagents arranged in a particular spatial order with discrete sections to allow for measurement of different biomarkers from a single bodily fluid sample.FIG. 2 is a schematic of one exampletest panel device 10 in which fiveindividual test pads 12 are arranged in a particular spatial order along the length of thetest panel device 10. In other embodiments a single test pad may be embedded with different reagents in a discrete spatial arrangement to provide a similar result. In either case, the entiretest panel device 10 may be exposed to a single bodily fluid sample (through dipping, dropwise addition, spraying, other fluidic transfer, or other). - In some invention embodiments that utilize urine, adjustments are made to account for the concentration of the urine specimen. The concentration of biomarkers in urine specimens can depend on an individual's hydration status, time since last urination, and other factors. In some embodiments, test subjects may be directed to follow certain instructions prior to fluid sample collection, such as not urinating for at least 30 minutes prior to the sampling, restricting the intake of fluids on the day (or other period of time) in which the sample is to be obtained, avoiding caffeinated beverages, following other dietary guidelines for a particular time period, and the like. In addition to these steps, some embodiments further include quantitative measurement of a parameter associated with urine concentration. Some invention embodiments may measure the creatinine level in a urine sample and/or the specific gravity of the sample as an indicator of the relative concentration of the sample. Urine specific gravity is the ratio of the density of a urine specimen to the density of water, and increases with solute concentration. It can be measured, for example, by refractometry. Alternatively, dry chemistry technology can be used in which a change in color is directly proportional to the specific gravity of the sample at a given pH value. Creatinine is a byproduct of muscle activity, and is cleared from the bloodstream by the kidneys and excreted in urine. Urinary creatinine concentrations can be determined by colorimetric assay, and analyte concentrations are usually reported as a ratio of the analyte concentration to creatinine concentration. Creatinine is typically present in urine in a generally known range. Likewise, urine typically has relatively known specific gravity ranges, and the average specific gravity of random urine specimens for individuals within a population have been reported (e.g. 1.020 for North American adults).
- Embodiments of the invention can measure one or more of these and use the measurement to estimate urine concentration. In some embodiments, the measurement is used as a pass/fail determination—if in an allowed range the sample is deemed acceptable and vice versa, but no changes to the bodily fluid measurements are made. In other embodiments bodily fluid measurements are adjusted or normalized based on the estimated urine concentration.
- In one embodiment, the concentration of creatinine in the specimen is measured using a discrete dry chemistry test pad, the general compositions of which are known and need not be discussed in detail herein for sake of brevity. If the creatinine concentration falls within a specified range, then the measured values for all of the biomarkers measured by the
test panel device 10 are divided by the concentration value obtained for creatinine and may be expressed in common units such as micrograms/milligram of creatinine. In this embodiment, if the concentration of creatinine is below a specified value (e.g. below 10 mg/dL in some but not all embodiments) then in some invention embodiments the sample may be considered too dilute to permit accurate analysis of the biomarkers therein, and a report may be generated indicating that the sample is too dilute and that the subject should provide another sample at a later time to permit more accurate analysis. In some embodiments employing creatinine for normalization, an upper limit may also be specified to improve accuracy since the relationship of the color produced in typical creatinine dry chemistry technologies is logarithmically related to the concentration of the specimen such that the change in color approaches a plateau value at high levels of creatinine. In this case, (a) a report may be generated indicating that the sample is too concentrated to permit accurate measurement of biomarkers, (b) the operator may dilute and reanalyze the sample, or (c) a fixed high creatinine value may be used for normalization of concentrated specimens. - In another embodiment the specific gravity, measured by refractometry or by a discrete channel or dry chemistry test pad or other method, the general steps of which are well established and need not be discussed herein for sake of brevity, is used for normalization. Further, given the known dependence of the typical colorimetric methods for measurement of specific gravity on the pH of a sample, an additional test pad or channel may be included in the
test panel device 10 to measure the pH of the specimen, and this value may be applied to mathematically correct the apparent specific gravity measurement for improved accuracy of the normalization process in some but not all embodiments. As for normalization employing creatinine, if the specific gravity falls within a specified range (e.g. 1.003-1.040 in some embodiments), then the measured values for all of the biomarkers measured by thetest panel device 10 are normalized based on the specific gravity measurement in some but not all embodiments. One algorithm that may be employed is to adjust the value obtained for each biomarker to that which would be observed in a sample with the specific gravity of the population norm. Thus, for North American adults, the sample concentration value is multiplied by (1.020−1.0)/(the specific gravity of the sample−1.0), so that for a specimen with a specific gravity of 1.010, the normalized value of a biomarker would be twice that of the measured value. - As for normalization to creatinine, if the specific gravity is below a specified value (e.g. below 1.003) then the sample is considered too dilute to permit accurate analysis of the biomarkers therein, and in some embodiments a report or indicator may be generated indicating that the sample is too dilute and/or that the subject should provide another sample at a later time to permit more accurate analysis. In this embodiment employing specific gravity, which is linearly related to the concentration of the specimen, there is less error introduced for concentrated specimens so that normalization is expected to be accurate over the entire specific gravity range for that population, provided that the raw or unnormalized concentrations of each biomarker lie within the measurable range for each of the discrete test pads or channels of the
test panel device 10. Thus normalizing concentration of each biomarker reported for an individual based on the concentration of the sample significantly improves the utility of urine biomarkers for evaluation of health and wellness compared to others within the population and for longitudinal tracking of an individual's health and wellness. It will be noted once again, however, that normalization is not necessary to all invention embodiments and some embodiments may find utility in avoiding any normalization steps. The example bodilyfluid test device 10 also includes a unique identifier (“ID”). - Because most applications for invention embodiments will be related to health and medical testing, it can be important to maintain a reliable and secure chain of identity—to ensure that the bodily data obtained using the
test panel device 10 is correctly associated with an individual subject that provided the bodily fluid and to ensure that the privacy of test results can be maintained. It is also useful to provide for the recognition by thetest reader 16 of specific lot numbers oftest panel devices 10, which may be valuable to avoid an operator using an expired lot, to reduce the possibility of inferior counterfeittest panel device 10 devices, to allow for lot-specific adjustments to standard curves or other parameters. It can also be used in combination with thereader device 16 to permit the analysis of multipletest panel device 10 configurations, such that the identifier encodes the nature and order of the dry chemistry or other analytical components and signals that the reader should analyze the reflectance or other physical change at specified wavelengths after specified time intervals. - One example way to benefit these needs is to provide each
test panel device 10 with a unique ID which can be recorded at the time of bodily fluid submission (or another time) and related to an individual test subject's name and/or other personal or identifying information. Many varieties of unique ID's can be provided with different invention embodiments. These include, but are not limited to, alphanumeric strings, one two or other dimensional barcodes, other optical means, radio frequency identifiers, and others. The schematic ofFIG. 2 illustrates one example unique ID 14 in the form of an optical bar code. Although the example ID 14 is illustrated on the same surface as thepads 12, in some embodiments it may be useful to orient it on the opposite or another different surface for compactness. - The bodily
fluid test device 10 is submitted to atest reader 16 for measurement of the concentrations of a set of biomarkers in a bodily fluid. Thetest reader 16 may be configured in many different manners in different invention embodiments. In some embodiments a test reader may be a dedicated electronic device that is connected to a processor based device such as a computer that controls it, records the resultant data as well as other biometric information that may be manually or electronically added to the file, performs the normalization, generates a report for that sample. The connection may be through a traditional BUS or other analog/digital connection. In other embodiments a different test reader may be integral with a computer, or may otherwise include a processor, memory, display and other computer related components. Many other potential test readers are contemplated in other embodiments. As an example, in still other embodiments a test reader may be a highly compact, portable and wireless handheld device that optically scans atest panel device 10. - In the attached FIGS., the test reader is illustrated as a stand-alone
electronic device 16A connected to aseparate computer 16B. “A” and “B” designations have been used with the two components inFIG. 1 to indicate that they may be considered in the context of some invention embodiments as two parts of a single component. Thecomputer 16B may be a traditional commercial laptop or other computer that includes one or more processors, a non-volatile (such as a magnetic or optical memory) and volatile memory(s) (such as a RAM memory), data input such as a keyboard, mouse, disk drive, optical reader or other device, display such as a monitor, microphones, cameras, speakers and the like. Thecomputer 16B may be executing a program product of the invention, a client incidence of a client-server program product of the invention, or other program product. Thecomputer 16B may also be a dedicated computer that has been configured only to operate within the scope of the invention. Because thetest reader 16A and associatedcomputer 16B operate in conjunction and in some embodiments are integral with one another, reference herein to “test reader” will be understood to include reference to both atest reader 16A andcomputer 16B and/or atest reader 16A orcomputer 16B that includes the functionality of the other. - In many embodiments, the
test reader 16 finds utility in portability. Portability allows for convenient use in applications such as mobile testing, for example. In an example application, employees at an office, factory or other location may be tested. Portability oftest reader 16 allows for convenient use in such applications, with a test operator traveling to the location and administering tests on site. This is particularly useful in applications that include testing of bodily fluid samples that have a relatively short time window of accuracy, with an example being many urine biomarker applications. In some urine testing embodiments, depending on the urine dipstick and other technology used, the sample may be refrigerated or treated with a preservative to impede bacterial growth. However, for greater accuracy in the analysis of a number of urinary biomarkers, preservatives or cold storage may influence the measured biomarker, so that the sample should be analyzed within a few hours—test results in some embodiments lose accuracy after this time period. In some embodiments, testing is performed within 1 hour, within 2 hours, within 3 hours, within 4 hours, or within other time limits. Portability helps address related issues since urine samples can be obtained on-site for groups and the like. - The
test reader 16 may operate in any number of different functional manners suitable for performing different bodily fluid measurements. As used herein, the term “bodily fluid measurements” is intended to broadly refer to measuring some aspect of a bodily fluid, including but not limited to measuring a biomarker contained within the bodily fluid, whether measured directly or indirectly. In many (but not all) embodiments a bodily fluid measurement includes a quantitative or semi-quantitative measurement of the presence or concentration of a biomarker. As used herein, a quantitative measurement is intended to broadly refer to one in which a relatively accurate numerical value (e.g., for a concentration) is determined, and a semi-quantitative measurement is one in which an approximate numerical value (e.g., for a concentration) can be estimated. Other embodiments include making qualitative measurements in which no numerical value is determined, but instead a determination is made regarding a quality indicator (e.g., color, pass/fail, presence/absence, other). - It will be appreciated that there are a multitude of potential manners of operation of different test readers of the invention to perform a bodily fluid measurement. Many aspects of the technical operation of a reader suitable for use in invention embodiments are known in the art and need not be detailed herein. The configuration of a particular test reader will depend necessarily on the configuration of the bodily fluid
test panel device 10. In most embodiments, a cooperating relationship exists between thetest panel device 10 andtest reader 16—thetest reader 16 necessarily is configured to measure concentration indicators that thetest panel device 10 is configured to indicate, and in particular to cooperate with the biomarker to be measured. One example bodilyfluid test reader 16 and cooperatingtest panel device 10 exploits chemical reagents embedded in the test panel device pads 12 (FIG. 2 ) that react with particular biomarkers within a bodily fluid components to produce a color change, with particular color indicative of the biomarker concentration. - Chemical compositions that produce colored products upon interaction with a number of biomarkers are generally known, but will be briefly described herein below. A wide range of chemical compounds are known to absorb light, with the result that exposing a compound to a known spectrum and measuring light that absorbed and/or reflected at or near certain wavelengths can be used to identify the presence of particular compounds, and/or their concentration. In embodiments of the invention that exploit this technology, the
test reader 16A is configured to employ photodiodes or other elements that emit light of particular wavelengths and/or intensity and photodetectors to measuring reflectance/absorbance to determine color and/or degree of color change. By comparison to results obtained for known standard biomarkers, the resulting reflectance/absorbance measurements can be converted to determine a particular biomarkers concentration within a bodily fluid using a known calibration that may be stored on thereader 16A, acomputer 16B or elsewhere. In addition to performing bodily fluid measurements, thetest reader 16A reads the unique sample and test panel ID 14 (FIG. 2 ) from thetest panel device 10. - The
test reader 16A may include various digital and analog components useful to perform the bodily fluid measurements, to read the unique ID 14, and to create a resulting test data set. For example, in anexample test reader 16A a plurality of light emitting and reflectance/absorbing measuring components may be spatially arranged to cooperate with thetest panel device 10 and its arrangement ofpads 12 and unique ID 14 (FIG. 2 ) so that measurements may be taken from eachpad 12 independently and unique ID 14 independently. The light emitting components direct a known spectrum of light toward the testpanel device pads 12, and the reflectance/absorbing components measure the resultant reflectance and/or fluorescence. A difference between the emitted and light due to reflection or fluorescence can be measured in toto or over a specific portion of the electromagnetic spectrum and used to determine presence and concentration of particular biomarkers based on their reaction with specific reagents. - Further,
test reader 16 andtest panel device 10 may be configured in a cooperating manner so that thetest panel device 10 is received in a particular and predictable orientation so thatpads 12 and unique ID 14 are located in a known location upon insertion of thetest panel device 10 in thetest reader 16. This can be accomplished in any number of manners, with examples including a mechanical arrangement featuring a cooperating slot or keyed arrangement, a motor driven loading tray that loads thetest panel device 10 along a consistent path to a known location. Atest reader 16A may also be provided with a digital checking mechanism that includes one or more location markers on thetest panel device 10 that are confirmed to be in their required locations before test reading was undertaken. In many embodiments, thetest reader 16 makes the plurality of bodily fluid biomarker measurements simultaneously for purposes of efficiency, speed of sample throughput and others. In some other embodiments, the measurements of different pads are not simultaneous, but done in series by a one or more scanners and other components that travel along the length of thetest panel device 10. - In some applications there can also be commercial advantages to including security information on the
test panel device 10. In some commercial applications, revenue will be received through sales oftest panel devices 10. In these applications, there may be risk that a competitor will reverse engineer thetest panel device 10 and sell competing products at a lower price that can be used with thetest reader 16. To mitigate the risk of this, including the potential for inferiortest panel device 10 counterfeits the results from which may not be derived from standard curve data for authentictest panel device 10, some embodiments oftest panel device 10 include digital or other security information that acts as a “key” for use of thetest reader 16. In these embodiments testreader 16 initially examines thetest panel device 10 searching for the presence of the security information before conducting a test. If the information is not present, no test is performed. The security information may be overt or covert, with some examples including a digital bar or other code (similar or identical to ID strip 14), a second digital or other code that in addition to ID strip 14, an RFID chip (which may be on or embedded within the test panel device 10), and others. - The above discussion has focused on a
test reader 16 andtest panel device 10 that utilize color change and cooperating optical measurement technology to measure biomarker concentration and/or presence. As indicated, many other technologies will be useful in other embodiments. These may include, but are not limited to, illumination at a specified wavelength of light and, e.g. by employing band pass filters, measurement of only the light emitted at a different wavelength by fluorescence, measurement of the refraction of light as it passes through a chamber within the FTD 10 device, (e.g. wherein the refraction of light may be used to determine the specific gravity to evaluate the relative concentration of a urine sample), the measurement of light emitted at a wavelength at which a specific chemical reaction used to quantify a biomarker does not exhibit any significant change in intensity with the biomarker concentration (known as the isobestic point) for purposes of internally calibrating the change in intensity at a second wavelength that is responsive to the concentration of the biomarker, control reaction pads that are sensitive to temperature and which can be used to detect exposure of the test panel device 10 to conditions that would damage its function, control chemical components in the test panel device 10 that may be used to quantify the relative amount of fluid that is taken up by the device and thus the amount of the sample being analyzed, control pads or channels that may be used to correct for endogenous absorption, reflection and/or fluorescence of light by the specimen (e.g. yellow or amber colors of urine or plasma specimens) and/or determination of the redox potential of a biofluid. - The
test reader 16 after performing bodily fluid measurements, with or without the separate input (manually or from remote data source) of additional biometric data on the individual being tested, creates a test data set. The test data set may include, for example, quantitative concentrations of biomarkers present in the bodily fluid measured by thetest panel device 10, normalized values after adjustment (e.g. based on creatinine or specific gravity values determined by the test panel device 10) in addition to a value corresponding to the unique ID 14. The test data set may be in the form of a digital file that includes numerical values representing biomarker concentrations, identifying and biometric information on the individual tested and an alphanumeric string that corresponds to the unique ID 14, for example, with one value corresponding to the concentration of each biomarker (and corresponding bodily fluid biochemical component) present in thebodily fluid sample 10. - The particular bodily fluid measurements made in invention embodiments will vary with application. Again, in many embodiments, a plurality of measurements are made simultaneously from a single
test panel device 10. In some embodiments, bodily fluid measurements that measure concentration of biomarkers that correspond to oxidative stress, anti-oxidative activity, and inflammation are useful. A number of different such bodily fluid measurements will be useful in different invention embodiments, with examples including the following: - TBARS (Thiobarbituric Acid Reactive Substances)
- Organic Hydroperoxides
- Protein Carbonyls
- Measure of oxidative damage to specific molecules
- Lipids
-
- Malonaldehyde
- 4-hydroxynonenal
- Lipid hydroperoxides
- Isoprostanes
- Linoleic acid oxidation products
- Proteins
-
- Protein carbonyls
- Nitrotyrosine
- Nitrothiols
- Nucleic Acids
-
- M1dG (malondialdehyde deoxyguanosine)
- 8-hydroxy-deoxyguanosine
- Oxidized derivatives of ribose ring
- Small Molecules and Ions
-
- Selenium
- GSH or GSSG and the GSH/GSSG ratio (Glutathione in reduced (GSH) and oxidized (GSSG) states)
- Direct Methods—Measure Reaction with Redox Probe
-
- CUPRAC (cupric reducing antioxidant capacity) Total Antioxidant Capacity or TAC (using copper-bathocuprione method)
- Indirect Methods (Measure Resistance to Oxidation of a Probe by an Added Oxidizer)
-
- FRAP (ferric reducing ability of plasma)
- TRAP (total reactive antioxidant potential)
- ORAC (oxygen radical absorbance capacity)
- HORAC (hydroxyl radical antioxidant capacity)
- Measurement of Molecules that Contribute to the Total Antioxidant Capacity
-
- GSH or GSSG and the GSH/GSSG ratio
- Glutathione Peroxidase
- Superoxide Dismutase
- Uric acid
- Ascorbic acid
- Cytokines (TNF-α, IL-6, IL-8)
- Other Proteins
-
- Osteopontin
- Albumin
- Orosomucoid
- α1-microglobulin
- Eicosanoids
-
- PGE2 and metabolites
- PGF2α and metabolites
- Other Molecules
-
- Nitric oxide byproducts (NOx=nitrate+nitrite)
- Urinary proteins
- Histamine
Biomarkers Associated with Hypertension - 20-HETE
- In one example embodiment, an oxidative bodily fluid measurement can incorporate either a relatively specific method to quantify malondialdehyde (MDA) or 4-hydroxyonenal (4HNE) as biomarkers for lipid peroxidation and/or the less specific thiobarbituric acid reactive substances (TBARS) method to measure a broader range of substances oxidized to aldehydes and ketones due to the actions of free radicals. These tests are known in the art and can be performed by an appropriate analyzing mechanism. Several other biomarkers can be used to test for oxidative damage to specific biomolecules or classes of biomolecules with some examples listed above. High levels of these biomarkers indicate the level of oxidative stress that is occurring in an individual, while low levels of these biomarkers indicate a relatively healthy individual.
- Oxidative stress occurs when an abnormal level of reactive oxygen species (ROS), such as superoxide and/or hydroxyl ions, and/or hydrogen peroxide, lead to damage of molecules in the body. ROS can be produced from fungal or viral infection, aging, UV radiation, pollution, excessive alcohol/tobacco consumption, drug metabolism, the uncoupling of electron transport systems in mitochondria, among other conditions. ROS can further cause many pathological conditions including age-related macular degeneration and cataracts, and is known to play a role in the development of multiple chronic
illnesses including type 2 diabetes, cancers and cardiovascular diseases. - Antioxidants help to control the level of ROS in the body and thus minimize oxidative damage to biomolecules and pathologies that may result. Tests have been developed to quantify many of the antioxidants that are produced by the human body. However, none of these have thus far been reduced to practice for the routine assessment of overall health and wellness. A number of complex tests have been developed to estimate the total level of all antioxidants in a specimen. Many of these tests, e.g. the ORAC test that is widely used to assess that antioxidant activity of foods and beverages, are intended for relatively sophisticated laboratories and involve the addition to a biological specimen of a dye that changes color upon oxidation, along with a source of ROS. In such tests, the higher the antioxidant activity of the specimen, the longer it takes for the dye to change color. Some embodiments of the invention utilize colorimetric tests for monitoring the antioxidant power of a biological sample due to multiple component antioxidants. These antioxidant power tests, sometimes called an antioxidant capacity tests, that employ copper-cuprione complexes (typically neocuprione or bathocuprione) or other complex that has a redox potential of approximately −0.6. In particular the CUPRAC (cupric reducing antioxidant capacity) method, which employs a copper-neocuprione complex, for measuring the sum of the antioxidant activity due to multiple endogenous as well as exogenous (e.g. antioxidants derived from food and vitamin supplements) is particularly useful for providing as integrated value for an individual's ability to maintain a healthy response to ROS.
- In some invention embodiments, further information may be included in the test data set. It may be useful in many embodiments that measure individual wellness data to collect various additional physical, personal and demographic data. As used herein the term demographic data is intended to broadly refer to data that may be useful to establish a related group. This might include, for example, demographic categories such as residence information, employer information, gender information, and other. In some embodiments, for example, additional information is provided by a test subject. This data may be manually provided through oral or written communications, or in another manner (with examples including scanning of an identity card such as a license/credit card, finger print scanning, retina scanning, and other). An operator can enter the information at the
computer 16B using a keyboard, mouse or other. In some embodiments, a credit card, license or other media with personal information can be scanned by thecomputer 16B. Personal, physical and demographic data that may be collected in invention embodiments includes but is not limited to demographic categories including: -
- Name
- Date of birth
- Social security number/Drivers license number/other government issued identification
- Height/weight/waist size/chest size/wrist and ankle diameter
- Gender/race/nationality
- Medical history (e.g., “history of high blood pressure,” “diabetic,” “allergies,” etc.)
- Family medical history (e.g., “history of high blood pressure in family,” “family history of cardiac issues,” etc.)
- Past or present marital status (e.g., “currently married,” “divorced”)
- Level of education (e.g., “high school graduate”, “2 years college,” etc.)
- Geographic residence (e.g., “current resident of Chicago, II” or “current resident of zip code 60606,” or “current resident of Alabama”)
- Tobacco use profile (example—“smoke 20-40 cigarettes per week,” or “smoke 4 cigars a month” or “do not use tobacco”)
- Alcohol use profile (example—“consume less than 1 drink per day” or “consume 2+ drinks per day” or “consumer 10-15 drinks per week”)
- Drug use profile (examples—“currently using anti-depressant” or “currently using anti-prescription inflammatory” or “currently using prescription blood pressure medication”)
- Exercise profile (examples—“vigorous exercise for at least 2 hours per week” or “
exercise 20 minutes per day” or “run 1 mile twice weekly”) - Vocation (e.g., “carpenter,” “office worker,” “professional,” “attorney,” “police officer,”)/Employer
- Contact information (physical residence address/e-mail address/work address)
- This and other data may be included with the test data set. Some of this information does not change, with an example being the name, gender, social security number and date of birth. This information that remains constant over time is referred to herein as “permanent personal information.” As will be detailed further below, in some invention embodiments individuals or groups may submit for multiple different tests over time. In such embodiments, this permanent personal information need not be represented every time a test subject submits a test, but instead can be recalled from prior tests for convenience. In some embodiments the
test reader 16 may also record a timestamp that corresponds to the time of measuring the bodily fluidtest panel device 10, and includes this timestamp with the test data set. The timestamp may be, for example, a day, month and year. It may be calculated using a clock internal to thetest reader 16, may be retrieved from thenetwork 20, may be manually input by an operator, or may otherwise be provided. - Also, for security or sensitivity purposes, some data (including demographic data) may be modified or otherwise adjusted. As an example, in some embodiments a user social security number could include only the final four digits or some other portion, the date of birth may be limited to only a month and year (no day), residence information may be limited to city and state only (no street), user names may be partial or assigned pseudo-names, and the like. In these embodiments, some advantage may be had in terms of security by not collecting and storing highly sensitive information such as a social security number.
- Once a test data set is created by the
test reader 16, the dataset with or without a copy of a comprehensive text profile generated based on algorithms that are dependent on the biomarkers and other data, is communicated over adata link 18 to anetwork 20, then to acentral computer 30. The data link 18 may be a wired or wireless link, with examples including a cellular phone communications link, a radio frequency connection, a PSTN communications link, a digital communications link, and the like. Similarly, thenetwork 20 may be any of a number of different communications networks, with examples including a wired or wireless phone network, PSTN, a digital network, a local area network, a wide area network, the internet, an internet successor such as the fast internet or next generation internet, a cellular communications network, combinations of one or more of these, and the like. - The
central computer 30 may be any number of processor based devices, with examples including a laptop, desktop, or server computer, a mainframe computer, and others. Thecomputer 30 may include one or more memories (volatile and/or non-volatile), one or more displays, one or more data input devices (with examples including keyboards, mouse, microphone, others). Thecentral computer 30 may be executing a program product of the invention, or a server incidence of a program product of the invention, and may have the same stored on a volatile or non-volatile memory. Although thecentral computer 30 has been illustrated as a single computer inFIG. 1 , it will be appreciated that in some embodiments thecentral computer 30 may include the functionality of a single computer spread across a plurality of computers. Indeed, current technology blurs the definition of computer, with many current devices including processors, memories and other components that are capable of executing stored instructions, storing data, and otherwise functioning as a computer. - In many embodiments, the
central computer 30 serves important data processing, organizing, storing, and reporting functions. In many (but not all) embodiments thecentral computer 30 stores in a memory, for example, average ranges for bodily fluid measurements that can be compared to the bodily fluid measurements from an individual test data set for calculation of a relative bodily fluid measurement. In some other embodiments, the reader 16 (and/orcomputer 16B) may store these average values in a memory so that these calculations of relative measurements can be made without access to thecentral computer 30. As used herein, the term “relative” when used in this context refers to a measurement that is compared to a population range of the same measurements. As an example, a relative measurement may include a percentile or scaled or similar ranked measurement, with the result that an individual's bodily fluid measurements may be reported in comparison to a larger universe for context (e.g., “oxidative stress level is in the 35th percentile,” or “oxidative stress is a 7.2 on a scale of 1 to 10,” etc.). - The central computer uses this stored data and the test data set communicated from the
test reader 16 to create a test output report. The test output report may be configured in any number of different forms as may be desirable. Indeed, as will be detailed below, one of the advantages of systems and methods of the invention is the ability to create highly customized test output reports to serve different needs. In many embodiments, however, the test output report will include a plurality of relative bodily fluid measurements in addition to some personal and demographic information.FIG. 3 illustrates one example test output report. - As illustrated in
FIG. 3 , the example test output report presents relative biomarker measurement results in a graphical format for convenience of consideration. Biomarker measurements that quantify oxidative damage, for example, are summarized by providing a numerical index for oxidative damage on a color coded line graph, with one end of the line and one color representing the lowest numerical value and corresponding best result, and the distal end of the line having a different (and often “opposite” with red and green being an example) color and representing the highest numerical value and corresponding worst result. This is a useful feature of some invention embodiments, using color to indicate results. Textual indicators may also be provided (e.g., “low, medium, high” or “reduced, elevated, highly elevated”, etc.) - It has been discovered that test output reports that present biomarker measurement results in this relative form are more easily understood and are more likely to have an impact on individuals. For example, it has been discovered that in the context of invention embodiments individuals appreciate health test results favorably through use of color coding which can include, for example, green for healthy readings, yellow for less healthy measurements, and red for most unhealthy measurements, with gradual color shading used to transition from one to the other.
- It has also been discovered that obtaining and providing a plurality of different relative bodily fluid measurements in a single test output report has similar benefits and advantages. The impact of multiple test results that may be related to one another appears to be much more impactful than a single test result might be. Also, some invention embodiments are directed to measuring an individual's so-called wellness (generally recognized as including metrics such as physical activity, body mass and lifestyle that are healthy and/or low levels of biomarkers that are indicative of risk for chronic illnesses), as opposed to diagnosis of a particular disease or ailment. These embodiments make measurements of biomarkers in body fluids useful to generally assess an individual's capacity to resist general classes of disease and ailments. For these embodiments, a test output report that includes a plurality of relative biomarker measurements in body fluids including the following has been discovered to be particularly useful: oxidative stress or damage (e.g. bodily fluid measurements of the biomarkers TBARS and MDS), inflammation (e.g. bodily fluid measurements of urinary protein and for NOx), and total antioxidant capacity (e.g. relative bodily fluid measurements of TAC). In addition to bodily fluid measurements, a test output report may include other results with one example including a body mass index (BMI) that is calculated based on input of an individual's height and weight. Other data such as age, ankle and/or wrist diameter, waist and chest diameter, may also be useful to assess wellness relative to one's peers. Some or all of the personal and demographic data may also be provided. The central computer also stores the bodily fluid test data set and the corresponding test output report in one or more memories.
- In some invention embodiments, the demographic data may also be used in formulating a test output report and/or test output data. Demographic data may be used in combination with numerical results to further estimate some aspects of a subject's wellness and disease risk and to provide information on the test output report. For example, demographic data indicating that a subject is a heavy smoker or heavy user of alcohol and that has an elevated level of a biomarker(s) for oxidative stress might be useful to provide a recommendation for lessening the oxidative stress level. At least some literature supports the proposition that smoking cessation reduces oxidative stress using one biomarker. Hence, individuals with high levels of oxidative damage and whose demographic data indicate they are a smoker may obtain a test output report identifying the smoking as a major source of oxidative stress and recommending cessation. Other literature show that exercise increases an individual's antioxidant capacity, so subjects that provide demographic data suggesting they are sedentary and who have with low values for an antioxidant biomarker(s) may receive a test output report that suggests increased exercise to improve antioxidant levels.
- Additionally, it is known that strenuous exercise increases oxidative stress biomarkers in the short term, but that the levels return to the basal level within 12-24 hrs. However, systematic exercise programs elevate the endogenous antioxidant levels, which otherwise deteriorate with age or reduced physical activity. So for test subjects that provide demographic data that indicate high levels of physical activity and whose test results indicate high levels of antioxidant biomarker(s) and oxidative damage biomarker(s), the report may indicate that they be retested after abstaining from strenuous exercise for some period of time (e.g., 24 hrs).
- Test output reports may be communicated as desired. Individuals that submitted a bodily fluid sample will be one destination for test output reports. These individuals may be mailed (by physical or electronic mail) a test output report. The test output report may be communicated over the
communications network 20 to acomputer 16B for printing on an attached printer (not illustrated), viewing on a display, or for storing in a memory for future use. Also, an advantage of many invention embodiments is that the test output reports are stored in a memory by thecentral computer 30 for presentation as desired. An individual may be provided access to thecentral computer 30 over the data network 20 (or otherwise) so that they can retrieve their test output report as desired whenever and wherever they may be. The individual may submit a request from a home computer, from a work computer, from a portable computer, from a portable communications device or from any number of other devices capable of communicating with thecommunications network 20. Again, for purposes of ensuring security of what may be sensitive information, test output report communication and storage may be encrypted. Storage and communication may utilize other high security measures to avoid data breach. - By way of example,
FIG. 1 shows amobile communications device 34 that may be a cellular phone, a radio phone, a radio, a smart phone, a gaming or entertainment device or other mobile processor based device that is in communication with thenetwork 20. An individual may use thismobile communications device 34 to communicate a request over thenetwork 20 to thecentral computer 30 for a test output report. Thecentral computer 30 may respond to this request by communicating the corresponding test output report to thecommunications device 34, which may display it on a local display, communicate it to another device (monitor or printer or other) for display or output, and/or store it in a memory for future use. - In order to associate an individual with their corresponding bodily fluid test data set and/or a corresponding test output report, the central computer necessarily must be able to identify the stored data with the individual referenced in the request it has received. There are a number of particular steps that can be undertaken to achieve this, but most have in common that some information included in the request can be used to identify the stored data. This may be, for example, personal data such as an individual's name, social security number, address or the like. Also, in many invention embodiments, the
test reader 16 andcentral computer 30 are configured to provide and recognize a unique security key that is associated with an individual. As used herein, the term “security key” is intended to broadly refer to a unique identifier that may be communicated digitally. It can be, for example, an alphanumeric string such as a password. - In some corresponding invention embodiments, the
test reader 16 is configured to provide the security key to the individual before the test data set is communicated to thecentral computer 30, while in other embodiments a request is communicated to the central computer to create a security key which is then communicated to thetest reader 16 before the test data set is communicated to thecentral computer 30. In still other embodiments, the initial test data set may be communicated to thecentral computer 30 which then creates a corresponding security key and communicates it to thetest reader 16. Individuals may also be permitted to create a desired security key for convenience. - In some embodiments more than one security key is provided. As an example, an individual may be asked to create a username and password (each of which may be a security keys in the context of the invention). In these embodiments, the central computer may confirm that the user name and password are available for use through a dialogue, and then assign these to the individual as well as corresponding test data sets and test output reports. Indeed, data used in various invention embodiments may include sensitive personal information, including identification and health related data. Some invention embodiments may include numerous features to ensure a high level of data communication, storage and reporting security. This may include, for example, multiple security keys, data encryption, highly reliable storage procedures, and the like. Data communicated to and from
central computer 30, including but not limited to test data sets and test output reports, may be encrypted. In some embodiments encryption may include installation of a client codec on client devices, sharing of a digital encryption key between client and server, and the like. - It may also be useful for one or more others to have access to test data sets and test output reports in addition to the individual that submitted the bodily fluid test sample. Health care professionals that care for the individual, relatives, employers, insurers and others are some examples of others that may find utility in accessing stored test data sets and/or stored test output reports. In these embodiments, the individual can provide his security key to others as he desires so that they can access stored data. Or, in some other embodiments the
test reader 16 and/or thecentral computer 30 are configured to provide one or more additional security keys. In some embodiments different security keys may carry different levels of access, with a first security key allowing access to all stored data, a second security key providing access to only a limited subset of the stored data, a third security key providing access to a still further limited data set, etc. - It may also be useful to organize test data sets, test output reports and other data by groups and to treat that data as a group. Groups may be any number of individuals that are related to one another in some manner. As an example, an employer may contract to administer testing to all of its employees. In addition to providing test output reports to individual employees, in such embodiments the employer may wish to have access to the test output reports for all of its employees. Accordingly, the central computer may provide a security key to the employer that is common to all employees. The different security keys may have different levels of access so that a first security key can access more stored data than a second key. This can be useful, for example, so that an employer can access some but not all stored data for its employees, while employees can access all information.
- As discussed above, the
central computer 30 of invention embodiments provides unique benefits and advantages through novel data processing, organizing, segmenting, storing, and output features. Some of these features correspond to organizing test data sets into groups. Organizing data into groups may be useful for a variety of different purposes. Groups can be created using data stored by the central computer, or can be defined when submitting data. As an example, in some embodiments a group could be created using demographic data for all women between the ages of 30-35, for all individuals that reside in a particular geographic location (e.g., city, state, county, zip code(s), etc.), all individuals of a certain vocation, and any number of other selections using existing, stored data. In still other embodiments, a group can be created upon submission of initial test data sets. As an example, atest reader 16 operator may input data confirming that a data set to be created by the reader is part of a group. A plurality of corresponding test data sets may include a common group identifier, which may be an assigned alphanumeric string. - These and other aspects of data storage and organization of systems, methods and program products of the invention can be further illustrated through consideration of a portion of an example database of an invention embodiment as shown in
FIG. 4 . This database may be created by, stored on, and/or retrieved from a non-volatile memory (which may be magnetic, optical or other) that is within or accessible bycentral computer 30. AlthoughFIG. 4 illustrates a general chart, it will be appreciated that this is an example only and is provided as one example illustration of data that can be stored and organized by systems, methods and program products of the invention. In many embodiments, the data may be manipulated within the configuration of a relational database. In the example ofFIG. 4 , individual test data sets are organized as rows and categories of data organized by columns. This is a somewhat simple example for purposes of illustration, and it will be appreciated that some actual test data sets will include far more data. - As indicated, each example test data set includes an individual name, a username (representing a first security key), two additional security keys, a birthdate (DOB), a test date (date the test was given), residence, race (coded), group, gender, tobacco use profile (expressed in a code corresponding to severity of use), education (expressed in number of years), vocation (coded), body mass index (BMI—expressed in a code), and normalized (and/or un-normalized or raw) bodily fluid measurement values for five different biomarkers (BM1-BM5). This information can be organized as desired, and may be grouped as has been illustrated in
FIG. 4 , with “personal data” including DOB, race and gender (columns A-D); security information including three different security keys (columns E-G); other personal data including a group identifier for first and second groups (if any), residence address, tobacco use profile, education level, and vocation (columns H-M); actual test data including a test date and five individual bodily fluid measurements (organized as biomarker measurements or BM) (columns N-T), and a test ID (corresponding to data from ID strip 14 which may be a unique test identifier). It will be appreciated that the data ofFIG. 4 is an example only, and that in practice test data sets may include more, less, or different data, and may be organized in different manners. -
FIG. 4 shows BMI or body mass index. As is generally known, body mass index can be routinely calculated using weight and height. Body fat percentage estimation, and similar additional metrics, for example, can sometimes also depend on age, waist, chest, wrist, ankle and other measurements. In some invention so embodiments, the underlying data is included in the test data set and stored by thecentral computer 30 in a memory. In other embodiments, however, the underlying data is provided by a user, but the resulting calculation is performed and only that resulting value stored (as opposed to the underlying data). Also, in some embodiments these calculations are performed bycomputer 16B with only the resulting calculated value communicated to thecentral computer 30, while in other embodiments the underlying data is communicated to the central computer and the calculations made by thecentral computer 30. This illustrates an aspect of the present invention that will be appreciated related to interchangeability ofcentral computer 30 withcomputer 16B. It will be appreciated that many calculations and other tasks can be made by either of these. Selection of which to use will often be made for purposes of efficiency in many cases it may be more efficient to have one or the other computer perform a particular task. It will be appreciated that selection of one of the other will not escape the scope of the invention. - By way of further illustration of this aspect of the invention, in some invention embodiments the test output report can be generated (including making of all required calculations as described above) can be performed by the
local computer 16B. The local computer can store, for example, in a memory all of the data required to generate normalized or relative measurement data. This can be advantageous, for example, in applications in which anetwork 18 is not available and for other reasons. Again, encryption of the data report may be used in some embodiments for security purposes when it is stored and/or communicated over thenetwork 20. - To further illustrate various features of invention embodiments, assume that a company named “Acme” desires to estimate the overall wellness of its employees. Further assume that Acme has a facility in Chicago and one in Milwaukee. This information may be input by one or more operators using a
computer 16B,central computer 30 or other device overnetwork 20.Central computer 30 responds by creating a first group for Acme (indicated by “acme” inFIG. 4 , col. H) and a subgroup for each of the Chicago and Milwaukee facilities (indicated by “Chi” and “Mil” inFIG. 4 col. I). An operator, acomputer 16B, or thecentral computer 30 further creates a security key for Acme—“acmeJ23.” This security key may be communicated to an Acme manager or other representative of Acme to facilitate their access to stored test data sets and/or stored test output reports for Acme employees that will be created. - A plurality of employees at each of the Acme Chicago and Milwaukee facilities are then tested. Each employee provides a bodily fluid sample which may be urine. A different
test panel device 10 is exposed to each urine sample. Permanent personal data (FIG. 4 , col. A-D) and other personal data (Col. H-M) is collected for each individual employee Individual and associated with the corresponding test panel device 10 (FIG. 2 ). This can be accomplished, for example, by individual employees providing a paper form that is provided with their urine sample, bycomputer 16B retrieving the data from an Acme database accessible over computer network 20 (not illustrated), by an individual employee or other operator entering the data in response to queries or through a provided form oncomputer 16B or other computer accessible tonetwork 20, or through other appropriate steps. - Individual
test panel device 10 for each Acme employee are then read by afirst test reader 16 that is temporarily located at the Acme Chicago facility and by asecond test reader 16 that is temporarily at the Acme Milwaukee facility. Individual test data sets are created for each individual employee including the data as indicated inFIG. 4 . A username and password (constituting two different security keys) are created for each employee, either bycomputer 16B or bycentral computer 30. - This may be accomplished, for example, by
computer 16B requesting creation of a new individual account fromcentral computer 30 which responds by providing a unique username and password tocomputer 16B. An individual account may be thought of as a user identity that will be associated with one or more test data records.Computer 16B may have also included in its request tocentral computer 30 that the new account would be associated with the Acme group as well as the appropriate subgroup. Or, in an alternate embodiment, when creating the Acme group and Chicago/Milwaukee subgroups,central computer 30 may have been informed of the total number of employees to be tested at each facility (and in some embodiments their names) and created a corresponding number of new accounts. - Each individual
test panel device 10 is then read byreader 16A to make individual biomarker measurements BM1-BM5. The body mass index may be calculated bycomputer 16B (or may be calculated by central computer 30). An individual report may be created by thecomputer 16B and, along with the test data record communicated fromcomputer 16B over thelinks 18 andnetwork 20 tocentral computer 30.Central computer 30 stores the data records in a memory using the general organization as shown inFIG. 4 . By way of further illustration of the Acme hypothetical, the test data sets shown in rows 1-5 are stored, with those of rows 1-3 corresponding to Acme employees at the Chicago facility and rows 4-5 Acme employees at the Milwaukee facility. Again, it will be appreciated thatFIG. 4 that includes 5 Acme employee individual test data records represents an abbreviated example only, and that in practice tens, hundreds, thousands or more of test data records may be stored. -
FIG. 4 illustrates test data sets for two individuals that are associated with the AARP group (rows 6-7), and a test data set for an individual that is not associated with any group (row 8 for Hank Right). The AARP test data sets do not have a second group identifier (no entry in column I). This indicates that for the AARP group no sub-groups have been set up. The Hank Right test data set inrow 8 has no group association, which might result if Mr. Right, for example, submitted a bodily fluid sample for testing at his physician's office, at a pharmacy, or other location as an individual. - The final row of
FIG. 4 (row 9) is a second test data set for Joe Smith, one of the Acme employees. This test data set, however, is not associated with the Acme group, which could result if Mr. Smith submitted a second bodily fluid sample for testing at another time/location from the Acme business testing. The security data for this test data set overlaps with that of the earlier Smith test data set (shown in row 1), except that there is nosecurity key 3 associated with it (no entry in column G). The username (security key 1) andsecurity key 2, however, are the same as for the first Smith test (row 1). This might result if when submitting his second bodily fluid test sample, Mr. Smith submitted his existing username andsecurity key 2. This may be done, for example, by Mr. Smith filling out a paper form that is read by atest reader 16, by Mr. Smith entering the username and security key directly intotest reader 16 using a keyboard, microphone or other data input device, by Mr. Smith providing an identity card or other data carrying device that is read by atest reader 16, or in other steps. When one or both of thecomputer 16B orcentral computer 30 receives this information, they may respond by providing Mr. Smith's permanent personal data (columns A-D) from Mr. Smith's prior test that is constant. This data may be directly populated into the second test data set for convenience so that Mr. Smith need not be required to present it a second time. - The request received from Mr. Smith (or someone acting on his behalf) might specify particular desired report characteristics. These might be, for example, a request for a test output report including only relative data for BM1 and BM2.
- Additionally, the data of
FIG. 4 indicate that three different test data sets exist for Mr. Smith, each taken at a different time. The request for a test output report submitted by Mr. Smith may specify which of the different test data sets to use to create the desired test output report. Also, the request might specify that the test output report should include relative results calculated over time using multiple test data sets. In Mr. Smith's example, it might be useful for him to have a test output report that showed changes in relative biomarker measurements over time. This can be useful, for example, to measure changes in his biomarker levels over time as Mr. Smith attempts to modify his lifestyle (through changes in diet, exercise, or other), or conversely a decline in wellness due to age and no lifestyle changes. Similarly, a group such as Acme could request to view results for its group as they change over time. Aggregate data for Acme employees may also prove useful for Acme to obtain lower rates for coverage. - As indicated above, some of the advantages and benefits of invention embodiments are related to the operation of the central computer in generating highly customizable and useful test output reports. This can be accomplished using the data organized in the table of
FIG. 4 .FIG. 5 illustrates one example set of steps for generating a test output report which may be embodied in a method or program product embodiment of the invention, or performed by a system of the invention. In discussing the flowchart ofFIG. 5 , it will be appreciated that various elements ofFIG. 1 (and in particular the central computer 30) and data ofFIG. 4 will be referenced. Element numbers of these FIGS. will be understood to refer to those FIGS. - The
central computer 30 first receives a request for a test output report from the network 20 (block 52). The request may be communicated from an individual such as Mr. Smith, an employer such as Acme, a health care provider representing an individual, or from another source. It can be communicated using any device in communication with thenetwork 20, includingcomputer 16B,smart phone 34, or other device. - The central computer then queries the request to identify what individual(s) a test output report is desired for (block 54). This step also includes the central computer confirming that that request has presented sufficient security key(s) to access the requested data (block 54). If the proper security keys are not provided, an error message results (block 58) and no data is provided. If a request includes proper security keys, the process of collecting and organizing data continues (block 60).
- By way of further illustration with regard to resolving security keys, a request may have been received for an output report that specifies the name “Hank Right” or otherwise specifies Mr. Right as shown in
row 8 ofFIG. 4 . In order for the central computer to proceed, the request must necessarily identify Mr. Right and include one or more of the required security keys shown in columns E-G ofFIG. 4 . As previously discussed, some invention embodiments allow for different levels of data access to be provided with different security keys. As an example, a first request that specifies a test output report based on Mr. Right's data could include the username “Left1” and second security key 899925 shown in columns E and F. The central computer may recognize the inclusion of these two security keys as a signal to allow full access to the Mr. Right's data included inrow 8. This username and second security key may have been provided, for instance, to Mr. Right, with the understanding that he would use these to retrieve his test data when desired. - A different request received by the central computer that specifies Mr. Smith may include the third security key shown in col. G of
FIG. 4 (Q88P), but not the first or second security keys. The central computer when executingblock 56 will recognize this as a signal to provide only limited access to the data. As an example, the access may be limited to only the test data of columns N-S but no other data fromrow 8. Or, limited access may allow for test data of columns N-S as well as selected (but not all) other personal data and permanent personal data. Many variations may be practiced as desired. - Referring once again to
FIG. 5 , after the proper security keys have been confirmed, the request is queried for details of the desired output report. As discussed above, some benefits and advantages of embodiments of the invention relate to highly capable, versatile and customizable data processing and reporting capabilities of thecentral computer 30 and/orcomputer 16B. Accordingly, in some invention embodiments test output reports are highly customizable and corresponding requests for an output report may specify details of what is desired on the test output report. The input of such detail may be provided through an on-line menu on a processor based device in communication with the network 20 (withexamples including computer 16B and portable device 34), through paper forms, or through other means. Also, for convenience, one or more standard output reports may be offered that provide pre-selected relative bodily fluid measurements. Examples of particular output reports will be provided below through further illustration of various invention embodiments, with one such example report illustrated inFIG. 3 and discussed above. - In almost all output reports data from a test data set will be required. In the manner generally discussed above, the
central computer 30 retrieves required data from the corresponding test data record(s) (block 62). Again, the required data will vary depending on details of the desired output report. Many requests will require retrieval of only a single test data set, while others may require retrieval of a plurality. As also discussed above, many embodiments feature output reports that provide relative data. This has been discovered to offer unique benefits and advantages as discussed above. To provide relative data, an individual test data set is compared to a larger universe of data to provide further context. A wide variety of universes may be selected and will be determined by the central computer through specifications in the request (block 64). - The
central computer 30 may store the universe data in a memory (local or accessible over network 20). Taking the BMI data fromFIG. 4 as an example, thecentral computer 30 may store a universe for BMI data that includes a mean, median, standard deviation(s), maximum, minimum and other statistical averages from across tens of thousands of samples that shows an expected range of from 18 to 30, with a mean of 23.2 and median of 23.7. The universe data may be segmented as desired according to demographic categories, with examples being universe data presented by gender, age, occupation, residence, or any other desired demographic category. Universe data may be obtained from literature or other sources. - Also, in some invention embodiments, advantages and benefits are achieved by configuring the
central computer 30 to develop universe data as desired using stored test data sets, as reflected inblock 64. Development of universe data is further customizable in invention embodiments as may be desired. It has been discovered, for example, that great utility can be achieved by allowing users to define their own universe. As an example, the Acme employer or an individual Acme employee may wish to view the results of his biomarker measurements relative to the universe of all Acme employees. In this case, test output reports for an individual could be prepared which compared that individual's BM1 measurement to the overall universe of BM1 measurements of all members of the Acme group. - The
central computer 30 accomplishes this by retrieving all records specifying the Acme group identifier in column H of the table ofFIG. 4 . Or, the particular employee may wish to compare their results to only female Acme employees that use tobacco, are married, are accountants, and live in Chicago. Again, thecentral computer 30 could accomplish this by selecting corresponding records from the table ofFIG. 4 . Although this universe may appear somewhat arbitrary, it is useful to illustrate the capabilities of invention embodiments in developing a desired universe across a great variety of potential variables that may be useful for one or another reason. A number of universes may be developed using any number of different stored demographic and personal data. Thecentral computer 30 may facilitate selection of the desired universe through presentation of menus or other graphical selection criteria to a user over thenetwork 20. - Referring again to
FIG. 5 , once the corresponding universe has been retrieved or developed, relative bodily fluid measurements are calculated and the test output report assembled (block 66). The output report may include relative bodily fluid measurements as desired and specified by a user, with an example shown inFIG. 3 . In many output reports, advantages and benefits are gained by providing a plurality of biomarker measurements. Relative biomarker measurements may be presented in a graphical form as discussed above and illustrated inFIG. 3 , any may include a color grading to aid comprehension. Additional information may be presented in the output report, including but not limited personal information, group information, or other. The assembled output report is then communicated over thenetwork 20 for storage, display, printing or other use at a remote device such ascomputer 16B,portable device 34, or the like (block 66). - In some embodiments availability of various output reports will also vary with level of security key access. As an example, a representative of the Acme employer may wish to view overall results for the universe of Acme employees, or a selected sub-group such as the Acme Milwaukee facility, male employees between the ages of 30 and 35, or other. The Acme representative may have been provided only the security key “AcmeJ23” shown in column G of
FIG. 4 . Presentation of this security key in the request communicated to thecentral computer 30 may allow for access to only limited portions of the test data sets for the Acme employees, with an example being the test data (FIG. 4 , columns N-S) but no, or in some embodiments a limited set, of personal and permanent personal data. This may be useful to protect some portions of personal data. In other embodiments, presentation of a particular group level security key such as the AcmeJ23 of column G will provide access only to statistical values representing the overall group data but not any single test data set. So, by way of illustration, in some embodiments presentation of the AcmeJ23 security key serves as a signal for the central computer to include on a test output report only the average, range, mean, median and other statistical values for the Acme group, but not any individual biomarker measurement data. - Test output reports may also present biomarker measurement data taken over time. Again, it has been discovered that this allows for benefits and advantages related to individuals and groups being able to measure changes over time as behavior, diet, and other factors change. A request processed by the central computer may specify, for example, that a particular user desires to have all their bodily fluid measurements charted over time, either in raw (i.e., not relative) form or in relative form. This could be accomplished, for example, by a user specifying some or all of their permanent personal data, security key information, or other data that is associated with each of their test data sets, and the
central computer 30 then using this to search a memory or database and identity every test data set that corresponds to that user. Referring toFIG. 4 by way of example, Joe R. Smith has two test data sets (rows 1 and 9) which each have common first and second security key information as well as permanent personal data. - The unique data gathering, storing and reporting capabilities of invention embodiments can be exploited in a number of other ways to offer other valuable benefits and advantages not previously available. As an example, the data stored by invention embodiments can serve as the basis for predictions of future events. As an example, correlations can be utilized to predict future rates of incidents of various diseases, health care costs, and the like for groups or individuals. A correlation could be referenced, for example, that associates the average BM1, BM2, BM3 and BM4 for the Acme employer to predicted health care costs for the coming years. Acme might provide access to its
security key 3 to an actuary or other entity that could review data and make such predictions. - Embodiments of the invention also include developing such correlations. Acme and other employers could provide their health care costs by year, for example, which can then be compared to average bodily fluid measurement data to create a health care cost correlation. Such predictive data will find utility in a multitude of applications. One example includes actuarial applications for insurance companies. An insurance company providing insurance cost estimates or determining annual premiums for the Acme company, for instance, could find great use in having all Acme employee test data records and applying a correlation factor to their average measurements to predict future health care costs.
- In further invention embodiments, comparisons of different groups' statistical data values can be made for predictive purposes or other purposes. As an example, assume that a
central computer 30 of the invention stores test data sets for 17 different Acme facilities, each located remotely from the other. If Acme is considering closing one facility, expanding one facility, it could find utility in comparing statistical data for each different facility to identify those that may have particularly high or particularly low relative bodily fluid measurement data (e.g., particularly healthy or unhealthy facilities). Doing so may be useful to predict expected relative health care costs which can aid decision making. Similarly, Acme may wish to identify which of its 17 facilities has the healthiest workforce so that other facilities can model operations on that facility. - Still other embodiments include further features of analyzing data sets. As the system acquires new data sets, multiple data analysis and cultivation opportunities are presented. Indeed, an important advantage of some invention embodiments lies in their scalability. As the volume of data collected grows, the value of statistical and other information to be gained from the data grows. Analysis of accumulated data is not limited to averages for populations or groups. As an example, as data sets are added, some embodiments further interrogate and identify subgroups at a highly granular level. Such identification can be useful to achieve further predictive usefulness.
- In addition to a relatively straightforward subgroup such as Acme employees from one factory, an illustrative example includes identifying a subgroup based on a behavioral change. Data sets for users that stop smoking, begin exercising, or have other behavior change(s) may be useful to offer guidance for others considering the same change as to how data will change in the future and otherwise what to anticipate in the future. Changes other than behavior can be used as well, with examples including loss of a specified amount of weight, geographic moves, employment changes, and others. Further, analysis may be performed from a results perspective going backward to identify subgroups. As an example, some embodiments may employ statistical analysis to identify common traits among users that have reported some measureable change in one or more biomarkers or other data (e.g., a weight loss of 10% or more). Some subgroup may be identified through such analysis that share some common trait(s).
- In still another embodiment, a further security key(s) may be provided to access multiple different groups for comparison sake by a third party. Assume that in addition to Acme, the data of
FIG. 4 includes group data for a multitude of other companies. An insurance company that is quoting insurance to two of those companies may find utility in accessing the overall statistical values for each company to compare them to one another and determine which should be quoted a higher insurance cost. Similarly, if a third company is considering acquiring Acme or one of its competitors, it may find value in accessing the overall statistical values for each company to compare them to one another and determine which is likely to have higher health care costs in the future. These example embodiments illustrate that some benefits and advantages of some invention embodiments will increase with scale—as more bodily fluid measurement data sets are collected the statistical value of the data to various third parties increases. - Invention embodiments offer still further opportunities to achieve valuable benefits and advantages. As an example, in addition to test data, the central computer may receive, associate with a user and store in a database such as that illustrated in
FIG. 4 further data. An individual may upon providing sufficient security information (such as one or more security keys) communicate weight, blood pressure and date data to thecentral computer 30 so that this data is associated with the user's already stored data. In this manner, the data stored by the central computer may include other data in addition to data sets generated bytest readers 16, and may include other data directly input by users at a later time. This may be useful, for example, to create a single health or wellness data collection that a user can track over time to track changes that occur in not only their biomarker measurements but other data that does not require atest reader 16 to determine, with weight, blood pressure and other data being an example. Upon receiving a corresponding request, thecentral computer 30 may output any selected data in a graphical or other form. A user could, for instance, obtain a chart that plots their weight and other data over time. From a commercial standpoint, these central computer capabilities of allowing users to input and to store and output other data in addition to data sets fromtest reader 16 may provide significant commercial advantages. It may create additional reasons for users to access thecentral computer 30 which leads to higher traffic and therefore greater opportunities for advertising or other revenue. - In a still further example embodiment, advertising revenue is collected based on targeted advertising to users as they access data or otherwise interact with
central computer 30. Some system, method, and program product embodiments of the invention provide targeted advertising over thenetwork 20. As used herein, the term “targeted advertisement” is intended to broadly refer to selecting particular advertisements for specific users based on some data for that user, as opposed to using the same advertisement for all users. In invention embodiments the advertising is targeted based on some defined criteria using data stored by thecentral computer 30 related to particular users. In invention embodiments, the targeted ads may be determined based on test data sets, demographic data, or other data. - As an example, in some invention embodiments users that indicate they are high frequency exercisers may be targeted for exercise equipment advertising, users that are identified as having lost a significant amount of weight may be targeted for clothing advertisements (since they may need new clothing), users that indicate they are heavy alcohol users may be targeted for alcohol ads (or substance abuse treatment ads), suggestions for birthday dinners may be provided to a user in advance of a user birthday, and the like. Almost infinite opportunities will exist for targeted advertising as the scale of stored data grows. Advertisements may appear as pop-up or other visual content on a screen connected to the
network 20, may be in the form of telephone calls, e-mail instant or other electronic communications, paper mail, or other. - Still other features of some invention embodiments include automated communication of
test readers 16 over thenetwork 20. This can be useful to update software running ontest readers 16, to diagnosetest readers 16 that require maintenance, to automatically track status oftest readers 16, and for other purposes. In most embodiments, testreaders 16 require execution of some stored program code. Such code will be updated from time to time, with different versions being identified using different version numbers. Likewise, testreaders 16 may require periodic maintenance to check and/or repair operation of various components. In some invention embodiments, testreaders 16 are configured to communicate over thenetwork 20 withcentral computer 30 or other computer to address these tasks in an automated manner. - As an example, in some invention embodiments test
readers 16 are configured to communicate over thenetwork 20 with thecentral computer 30 or other computer on some regular interval to perform routine diagnostics. The diagnostics may check operation ofvarious test reader 16 components and operation, and may identifytest readers 16 or its components for repair. The interval may be selected as desired, with examples including every time thetest reader 16 connects to thenetwork 20, once a week, once a month, once quarterly, and once annually. - Likewise, in some embodiments test readers are configured to communicate over the
network 20 with thecentral computer 30 or other computer on some regular interval to check for operating software updates. Thetest reader 16 may compare the version number of its operating software with that of the most currently available version available over thenetwork 20, and if a more recent version is available it may automatically download the update. Again, the interval may be selected as desired, with examples including every time thetest reader 16 connects to thenetwork 20, once a week, once a month, once quarterly, and once annually. - Further, as described above in some embodiments test
readers 16 are configured to store data necessary to provide test output reports without accessing thecentral computer 30. In these embodiments, test readers will store universe data on a local memory so that relative output data can be calculated. This universe data may be updated from time to time. In some embodiments, such updates are done automatically on a desired interval over thenetwork 20. The test reader may communicate with thecentral computer 30 or other computer over thenetwork 20 to determine if updated universe data is available. If it is, thetest reader 16 may download it. - Various illustrations and discussion of example features of some invention embodiments has been made herein. It will be appreciated that this has been done by way of illustration only, and not limitation. Various features and elements of different embodiments can be altered, substituted for one another, omitted, changed in sequence or inter-relation, and otherwise altered within the scope of the invention as claimed.
Claims (23)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/397,360 US20120203465A1 (en) | 2010-07-26 | 2012-02-15 | Systems, methods and program products for collecting and organizing health data |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36748610P | 2010-07-26 | 2010-07-26 | |
| PCT/US2011/044786 WO2012018535A2 (en) | 2010-07-26 | 2011-07-21 | Wellness panel |
| US13/397,360 US20120203465A1 (en) | 2010-07-26 | 2012-02-15 | Systems, methods and program products for collecting and organizing health data |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/044786 Continuation-In-Part WO2012018535A2 (en) | 2010-07-26 | 2011-07-21 | Wellness panel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US20120203465A1 true US20120203465A1 (en) | 2012-08-09 |
Family
ID=45559970
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/812,220 Active US10161928B2 (en) | 2010-07-26 | 2011-07-21 | Wellness panel |
| US13/397,360 Abandoned US20120203465A1 (en) | 2010-07-26 | 2012-02-15 | Systems, methods and program products for collecting and organizing health data |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US13/812,220 Active US10161928B2 (en) | 2010-07-26 | 2011-07-21 | Wellness panel |
Country Status (2)
| Country | Link |
|---|---|
| US (2) | US10161928B2 (en) |
| WO (1) | WO2012018535A2 (en) |
Cited By (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130012786A1 (en) * | 2011-07-05 | 2013-01-10 | Saudi Arabian Oil Company | Chair Pad System and Associated, Computer Medium and Computer-Implemented Methods for Monitoring and Improving Health and Productivity of Employees |
| US20130012789A1 (en) * | 2011-07-05 | 2013-01-10 | Saudi Arabian Oil Company | Systems, Computer Medium and Computer-Implemented Methods for Monitoring and Improving Biomechanical Health of Employees |
| US20130012790A1 (en) * | 2011-07-05 | 2013-01-10 | Saudi Arabian Oil Company | Systems, Computer Medium and Computer-Implemented Methods for Monitoring and Improving Health and Productivity of Employees |
| US20130024387A1 (en) * | 2011-07-20 | 2013-01-24 | Verify Brand Llc | Systems and Methods for Tracking Assigned Code Strings |
| US20130057385A1 (en) * | 2009-09-21 | 2013-03-07 | Ensign Holdings. LLC | Systems and methods for securely monitoring an individual |
| WO2014039794A3 (en) * | 2012-09-06 | 2014-05-01 | Berkeley Test, LLC | Compositions, apparatus and methods for monitoring biomarkers |
| WO2014190234A1 (en) * | 2013-05-23 | 2014-11-27 | Iphenotype Llc | Method and system for maintaining or improving wellness |
| US9693734B2 (en) | 2011-07-05 | 2017-07-04 | Saudi Arabian Oil Company | Systems for monitoring and improving biometric health of employees |
| US9710788B2 (en) | 2011-07-05 | 2017-07-18 | Saudi Arabian Oil Company | Computer mouse system and associated, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US9722472B2 (en) | 2013-12-11 | 2017-08-01 | Saudi Arabian Oil Company | Systems, computer medium and computer-implemented methods for harvesting human energy in the workplace |
| US9739773B1 (en) | 2010-08-13 | 2017-08-22 | David Gordon Bermudes | Compositions and methods for determining successful immunization by one or more vaccines |
| US9889311B2 (en) | 2015-12-04 | 2018-02-13 | Saudi Arabian Oil Company | Systems, protective casings for smartphones, and associated methods to enhance use of an automated external defibrillator (AED) device |
| US9949640B2 (en) | 2011-07-05 | 2018-04-24 | Saudi Arabian Oil Company | System for monitoring employee health |
| US20180157944A1 (en) * | 2015-05-29 | 2018-06-07 | Terrence Keith Ashwin | Method and apparatus for selecting a wireless reader action as a result of an output data received from a wireless identification device |
| US10265700B2 (en) | 2016-11-11 | 2019-04-23 | Samuel Messinger | System for improving diabetes testing and reducing counterfeiting |
| US10307104B2 (en) | 2011-07-05 | 2019-06-04 | Saudi Arabian Oil Company | Chair pad system and associated, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US10475351B2 (en) | 2015-12-04 | 2019-11-12 | Saudi Arabian Oil Company | Systems, computer medium and methods for management training systems |
| US10628770B2 (en) | 2015-12-14 | 2020-04-21 | Saudi Arabian Oil Company | Systems and methods for acquiring and employing resiliency data for leadership development |
| US10642955B2 (en) | 2015-12-04 | 2020-05-05 | Saudi Arabian Oil Company | Devices, methods, and computer medium to provide real time 3D visualization bio-feedback |
| WO2020194830A1 (en) * | 2019-03-26 | 2020-10-01 | 株式会社ファーストスクリーニング | Urinalysis device and health facilitation system |
| US10824132B2 (en) | 2017-12-07 | 2020-11-03 | Saudi Arabian Oil Company | Intelligent personal protective equipment |
| US20210041353A1 (en) * | 2013-12-06 | 2021-02-11 | Quidel Corporation | Method for reducing analyzer variability using a normalization target |
| US11193949B2 (en) | 2017-02-21 | 2021-12-07 | Zoetis Services Llc | Diagnostic test reader system |
| US20220076846A1 (en) * | 2012-09-07 | 2022-03-10 | Hugh Macnaught | Comparison of user experience with experience of larger group |
| US11520890B2 (en) * | 2013-10-25 | 2022-12-06 | Ascensia Diabetes Care Holdings Ag | Hardware key system for device protection |
| US11587038B2 (en) * | 2013-03-20 | 2023-02-21 | Lifetime Brands, Inc. | Method and apparatus for mobile quality management inspections |
| US20230054322A1 (en) * | 2021-08-23 | 2023-02-23 | Leslie P. Taylor | Urine indication pad with inbuilt diagnostics for training and indication of potential disease |
| DE202022107224U1 (en) | 2022-12-23 | 2023-03-29 | Jalawi Sulaiman Alshudukhi | System for secure storage and transaction of health data in interconnected implanted medical devices and control servers |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014176556A1 (en) * | 2013-04-26 | 2014-10-30 | Express Diagnostics International, Inc. | Portable testing system for detecting selected drugs or compounds in non-controlled environments |
| WO2014201451A1 (en) * | 2013-06-14 | 2014-12-18 | Wellmetris Llc | Stress and inflammation biomarker urine panel for dairy cows and beef cattle |
| WO2015034886A2 (en) * | 2013-09-03 | 2015-03-12 | Wellmetris Llc | Wellness panel for companion animals |
| WO2015151023A1 (en) * | 2014-04-01 | 2015-10-08 | H&D S.R.L. | Method for the diagnostic determination of the risk caused by an altered oxidative balance |
| HK1250391A1 (en) * | 2015-03-23 | 2018-12-14 | Wellmetris, Llc | Smartphone enabled urinalysis device, software, and test platform |
| KR102614951B1 (en) * | 2015-12-10 | 2023-12-19 | 삼성전자주식회사 | Manufacturing method of pad for measuring concentration of target material, solution for manufacturing the pad, and strip using the pad |
| US20180136140A1 (en) * | 2016-11-15 | 2018-05-17 | Jon Brendsel | System for monitoring and managing biomarkers found in a bodily fluid via client device |
| WO2020028837A1 (en) * | 2018-08-03 | 2020-02-06 | Wellmetrix, Llc | Systems and methods for monitoring an individual's health |
| CA3049972A1 (en) * | 2019-07-15 | 2021-01-15 | Youcount Inc. | Urinalysis test strip for over-the-counter use |
| CN112582063A (en) * | 2019-09-30 | 2021-03-30 | 长沙昱旻信息科技有限公司 | BMI prediction method, device, system, computer storage medium, and electronic apparatus |
| CA3268137A1 (en) * | 2022-09-22 | 2024-03-28 | Herstasis Health Found | Device, method and system for diagnosing, monitoring and predicting chronic health conditions through urine biomarkers |
| CN120610012A (en) * | 2023-10-20 | 2025-09-09 | T&D诊断加拿大私人有限公司 | Markers and devices for diagnosing an individual's overall health status |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS55142249A (en) * | 1979-04-24 | 1980-11-06 | Shionogi & Co Ltd | Reduction type ascorbic acid detecting composition and test piece |
| US5801061A (en) | 1997-04-22 | 1998-09-01 | Environmental Test Systems, Inc. | Method for the colorimetric determination of analytes in the presence of interfering particulate materials |
| US6753159B1 (en) * | 1998-08-06 | 2004-06-22 | Jin Po Lee | Uric acid assay device with stabilized uricase reagent composition |
| US6372514B1 (en) | 1998-09-18 | 2002-04-16 | Syntron Bioresearch, Inc. | Even fluid front for liquid sample on test strip device |
| AU1243500A (en) | 1998-11-06 | 2000-05-29 | Emory University | Biomarkers for oxidative stress |
| EP1145005A3 (en) * | 1999-04-08 | 2001-12-05 | Chimera Research and Chemical, Inc. | Method for detection of analytes in urine using lateral flow hybrid device |
| US6514769B2 (en) * | 1999-07-29 | 2003-02-04 | Jin Po Lee | Multiple analyte assay device with sample integrity monitoring system |
| US6235495B1 (en) * | 1999-11-12 | 2001-05-22 | Oxis International, Inc. | Methods for the quantitation of oxidized glutathione |
| US20070021929A1 (en) * | 2000-01-07 | 2007-01-25 | Transform Pharmaceuticals, Inc. | Computing methods for control of high-throughput experimental processing, digital analysis, and re-arraying comparative samples in computer-designed arrays |
| US7476533B2 (en) | 2002-04-19 | 2009-01-13 | Adhesives Research, Inc. | Diagnostic devices for use in the assaying of biological fluids |
| CA2414073A1 (en) * | 2001-05-04 | 2002-11-14 | Gunars E. Valkirs | Diagnostic markers of acute coronary syndromes and methods of use thereof |
| US6541265B2 (en) | 2001-05-09 | 2003-04-01 | University Of Florida | Method and system to test a substance for inflammatory or oxidant properties |
| JP4829496B2 (en) * | 2002-06-14 | 2011-12-07 | ファイザー・インク | Metabolic phenotype |
| GB2391813B (en) | 2002-08-14 | 2006-03-29 | Cozart Bioscience Ltd | An oral fluid collection, transfer and transportation device and method |
| US7220597B2 (en) | 2003-01-30 | 2007-05-22 | Zin Benedict L | Assay test device and method of making same |
| US20050260695A1 (en) * | 2003-09-23 | 2005-11-24 | Genprime, Inc. | Methods, compositions, devices, and kits for detecting mastitis |
| US7927548B2 (en) | 2005-01-27 | 2011-04-19 | Bamburgh Marsh Llc | Specimen sample collection device and test system |
| CA2601720C (en) | 2005-04-01 | 2014-08-12 | Advanced Medical Products Gmbh | Body fluid testing component for analyte detection |
| US20060281188A1 (en) * | 2005-06-13 | 2006-12-14 | Cornell Research Foundation, Inc. | Ratiometric test strip and method |
| US8119358B2 (en) * | 2005-10-11 | 2012-02-21 | Tethys Bioscience, Inc. | Diabetes-related biomarkers and methods of use thereof |
| US20090215159A1 (en) | 2006-01-23 | 2009-08-27 | Quidel Corporation | Device for handling and analysis of a biological sample |
| US20080089843A1 (en) * | 2006-05-25 | 2008-04-17 | Reddy's Laboratories, Inc. | Use of biomarkers of inflammation as indicators of drug efficacy |
| US8871455B2 (en) * | 2006-06-12 | 2014-10-28 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Biomarker panels for assessing radiation injury and exposure |
| US20100021928A1 (en) * | 2006-06-26 | 2010-01-28 | Technion Research & Development Foundation Ltd. | Methods and kits for diagnosing cancer |
| US7749775B2 (en) | 2006-10-03 | 2010-07-06 | Jonathan Scott Maher | Immunoassay test device and method of use |
| JP2010528302A (en) | 2007-05-31 | 2010-08-19 | バイオクレイツ ライフ サイエンス エージー | Inflammation and oxidative stress level assay |
| CN102216758B (en) * | 2008-12-05 | 2013-07-17 | 红电医学科技股份有限公司 | Test strip reader with detachable firmware device |
| US9200324B2 (en) | 2009-10-15 | 2015-12-01 | Crescendo Bioscience | Biomarkers and methods for measuring and monitoring inflammatory disease activity |
| US20110312747A1 (en) | 2010-06-17 | 2011-12-22 | Geneasys Pty Ltd | Microfluidic device for biochemical processing and analysis |
| US20130165339A1 (en) | 2010-06-30 | 2013-06-27 | University Of South Florida | Sapp-alpha as a biomarker for prediction of inflammatory and autoimmune-related disorders |
| US9241663B2 (en) | 2012-09-05 | 2016-01-26 | Jana Care Inc. | Portable medical diagnostic systems and methods using a mobile device |
| EP2895852A4 (en) | 2012-09-11 | 2016-05-25 | Univ Cornell | APPARATUS AND METHOD FOR MEASURING ON THE COLLECTION POINT OF A BIOMOLECULAR REACTION |
| CN105164514A (en) | 2013-01-21 | 2015-12-16 | 康奈尔大学 | Smartphone-based device and method for obtaining reproducible quantitative colorimetric measurements |
-
2011
- 2011-07-21 US US13/812,220 patent/US10161928B2/en active Active
- 2011-07-21 WO PCT/US2011/044786 patent/WO2012018535A2/en not_active Ceased
-
2012
- 2012-02-15 US US13/397,360 patent/US20120203465A1/en not_active Abandoned
Cited By (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10911427B1 (en) | 2009-09-21 | 2021-02-02 | Halo Wearables, Llc | Reconfiguration of a wearable medical device |
| US10554648B1 (en) | 2009-09-21 | 2020-02-04 | Halo Wearables, Llc | Calibration of a wearable medical device |
| US20130057385A1 (en) * | 2009-09-21 | 2013-03-07 | Ensign Holdings. LLC | Systems and methods for securely monitoring an individual |
| US9584496B2 (en) * | 2009-09-21 | 2017-02-28 | Convergence Biometrics, LLC | Systems and methods for securely monitoring an individual |
| US9739773B1 (en) | 2010-08-13 | 2017-08-22 | David Gordon Bermudes | Compositions and methods for determining successful immunization by one or more vaccines |
| US9360490B2 (en) | 2011-03-10 | 2016-06-07 | Berkeley Test, LLC | Compositions, apparatus and methods for monitoring biomarkers |
| US9759716B2 (en) | 2011-03-10 | 2017-09-12 | Berkeley Nox Limited | Compositions, apparatus and methods for monitoring biomarkers |
| US10052023B2 (en) | 2011-07-05 | 2018-08-21 | Saudi Arabian Oil Company | Floor mat system and associated, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US10307104B2 (en) | 2011-07-05 | 2019-06-04 | Saudi Arabian Oil Company | Chair pad system and associated, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US9492120B2 (en) * | 2011-07-05 | 2016-11-15 | Saudi Arabian Oil Company | Workstation for monitoring and improving health and productivity of employees |
| US9526455B2 (en) * | 2011-07-05 | 2016-12-27 | Saudi Arabian Oil Company | Systems, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US20130012789A1 (en) * | 2011-07-05 | 2013-01-10 | Saudi Arabian Oil Company | Systems, Computer Medium and Computer-Implemented Methods for Monitoring and Improving Biomechanical Health of Employees |
| US9615746B2 (en) | 2011-07-05 | 2017-04-11 | Saudi Arabian Oil Company | Floor mat system and associated, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US9693734B2 (en) | 2011-07-05 | 2017-07-04 | Saudi Arabian Oil Company | Systems for monitoring and improving biometric health of employees |
| US9710788B2 (en) | 2011-07-05 | 2017-07-18 | Saudi Arabian Oil Company | Computer mouse system and associated, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US20130012790A1 (en) * | 2011-07-05 | 2013-01-10 | Saudi Arabian Oil Company | Systems, Computer Medium and Computer-Implemented Methods for Monitoring and Improving Health and Productivity of Employees |
| US9462977B2 (en) | 2011-07-05 | 2016-10-11 | Saudi Arabian Oil Company | Systems, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US10206625B2 (en) | 2011-07-05 | 2019-02-19 | Saudi Arabian Oil Company | Chair pad system and associated, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US9808156B2 (en) | 2011-07-05 | 2017-11-07 | Saudi Arabian Oil Company | Systems, computer medium and computer-implemented methods for monitoring and improving biomechanical health of employees |
| US9830576B2 (en) | 2011-07-05 | 2017-11-28 | Saudi Arabian Oil Company | Computer mouse for monitoring and improving health and productivity of employees |
| US9830577B2 (en) | 2011-07-05 | 2017-11-28 | Saudi Arabian Oil Company | Computer mouse system and associated computer medium for monitoring and improving health and productivity of employees |
| US9833142B2 (en) | 2011-07-05 | 2017-12-05 | Saudi Arabian Oil Company | Systems, computer medium and computer-implemented methods for coaching employees based upon monitored health conditions using an avatar |
| US9844344B2 (en) * | 2011-07-05 | 2017-12-19 | Saudi Arabian Oil Company | Systems and method to monitor health of employee when positioned in association with a workstation |
| US10058285B2 (en) | 2011-07-05 | 2018-08-28 | Saudi Arabian Oil Company | Chair pad system and associated, computer medium and computer-implemented methods for monitoring and improving health and productivity of employees |
| US9949640B2 (en) | 2011-07-05 | 2018-04-24 | Saudi Arabian Oil Company | System for monitoring employee health |
| US9962083B2 (en) * | 2011-07-05 | 2018-05-08 | Saudi Arabian Oil Company | Systems, computer medium and computer-implemented methods for monitoring and improving biomechanical health of employees |
| US20130012786A1 (en) * | 2011-07-05 | 2013-01-10 | Saudi Arabian Oil Company | Chair Pad System and Associated, Computer Medium and Computer-Implemented Methods for Monitoring and Improving Health and Productivity of Employees |
| US20130024387A1 (en) * | 2011-07-20 | 2013-01-24 | Verify Brand Llc | Systems and Methods for Tracking Assigned Code Strings |
| WO2014039794A3 (en) * | 2012-09-06 | 2014-05-01 | Berkeley Test, LLC | Compositions, apparatus and methods for monitoring biomarkers |
| US20220076846A1 (en) * | 2012-09-07 | 2022-03-10 | Hugh Macnaught | Comparison of user experience with experience of larger group |
| US11587038B2 (en) * | 2013-03-20 | 2023-02-21 | Lifetime Brands, Inc. | Method and apparatus for mobile quality management inspections |
| WO2014190234A1 (en) * | 2013-05-23 | 2014-11-27 | Iphenotype Llc | Method and system for maintaining or improving wellness |
| US10278624B2 (en) | 2013-05-23 | 2019-05-07 | Iphenotype Llc | Method and system for maintaining or improving wellness |
| US11520890B2 (en) * | 2013-10-25 | 2022-12-06 | Ascensia Diabetes Care Holdings Ag | Hardware key system for device protection |
| US11953428B2 (en) * | 2013-12-06 | 2024-04-09 | Quidel Corporation | Method for reducing analyzer variability using a normalization target |
| US20210041353A1 (en) * | 2013-12-06 | 2021-02-11 | Quidel Corporation | Method for reducing analyzer variability using a normalization target |
| US9722472B2 (en) | 2013-12-11 | 2017-08-01 | Saudi Arabian Oil Company | Systems, computer medium and computer-implemented methods for harvesting human energy in the workplace |
| US20180157944A1 (en) * | 2015-05-29 | 2018-06-07 | Terrence Keith Ashwin | Method and apparatus for selecting a wireless reader action as a result of an output data received from a wireless identification device |
| US11347983B2 (en) * | 2015-05-29 | 2022-05-31 | Hive Technology | Method and apparatus for selecting a wireless reader action as a result of an output data received from a wireless identification device |
| US10475351B2 (en) | 2015-12-04 | 2019-11-12 | Saudi Arabian Oil Company | Systems, computer medium and methods for management training systems |
| US10642955B2 (en) | 2015-12-04 | 2020-05-05 | Saudi Arabian Oil Company | Devices, methods, and computer medium to provide real time 3D visualization bio-feedback |
| US9889311B2 (en) | 2015-12-04 | 2018-02-13 | Saudi Arabian Oil Company | Systems, protective casings for smartphones, and associated methods to enhance use of an automated external defibrillator (AED) device |
| US10628770B2 (en) | 2015-12-14 | 2020-04-21 | Saudi Arabian Oil Company | Systems and methods for acquiring and employing resiliency data for leadership development |
| US10265700B2 (en) | 2016-11-11 | 2019-04-23 | Samuel Messinger | System for improving diabetes testing and reducing counterfeiting |
| US11193949B2 (en) | 2017-02-21 | 2021-12-07 | Zoetis Services Llc | Diagnostic test reader system |
| US10824132B2 (en) | 2017-12-07 | 2020-11-03 | Saudi Arabian Oil Company | Intelligent personal protective equipment |
| JP2021089296A (en) * | 2019-03-26 | 2021-06-10 | 株式会社ファーストスクリーニング | Urinalysis device and health assistance system technology field |
| JPWO2020194830A1 (en) * | 2019-03-26 | 2021-04-08 | 株式会社ファーストスクリーニング | Urinalysis equipment and dietary supplement system |
| JP7454856B2 (en) | 2019-03-26 | 2024-03-25 | 株式会社ファーストスクリーニング | urine test device |
| WO2020194830A1 (en) * | 2019-03-26 | 2020-10-01 | 株式会社ファーストスクリーニング | Urinalysis device and health facilitation system |
| US20230054322A1 (en) * | 2021-08-23 | 2023-02-23 | Leslie P. Taylor | Urine indication pad with inbuilt diagnostics for training and indication of potential disease |
| DE202022107224U1 (en) | 2022-12-23 | 2023-03-29 | Jalawi Sulaiman Alshudukhi | System for secure storage and transaction of health data in interconnected implanted medical devices and control servers |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012018535A2 (en) | 2012-02-09 |
| WO2012018535A3 (en) | 2012-06-07 |
| US20130122518A1 (en) | 2013-05-16 |
| US10161928B2 (en) | 2018-12-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120203465A1 (en) | Systems, methods and program products for collecting and organizing health data | |
| DeSalvo et al. | Predicting mortality and healthcare utilization with a single question | |
| Middleton et al. | Life expectancy after spinal cord injury: a 50-year study | |
| US20210098099A1 (en) | Systems and methods for selecting a treatment schema based on user willingness | |
| DuBrava et al. | Using random forest models to identify correlates of a diabetic peripheral neuropathy diagnosis from electronic health record data | |
| Beydoun et al. | Pathways explaining racial/ethnic and socio-economic disparities in incident all-cause dementia among older US adults across income groups | |
| Shim et al. | Wearable-based accelerometer activity profile as digital biomarker of inflammation, biological age, and mortality using hierarchical clustering analysis in NHANES 2011–2014 | |
| Amiri et al. | Depression and risk of disability pension: a systematic review and meta-analysis | |
| Zeugswetter et al. | Point‐of‐care β‐hydroxybutyrate measurement for the diagnosis of feline diabetic ketoacidaemia | |
| US20180340927A1 (en) | Systems and methods for monitoring an individual's health | |
| Kim et al. | Dried blood spot based biomarkers in the Health and Retirement Study: 2006 to 2016 | |
| Zam et al. | A first country-wide review of diabetes mellitus care in Bhutan: time to do better | |
| Muszyńska-Spielauer et al. | Well-being adjusted health expectancy: a new summary measure of population health | |
| Peele | Domains of childhood disadvantage and functional limitation trajectories among midlife men and women in China | |
| McCleskey et al. | Review of postmortem interval estimation using vitreous humor: past, present, and future | |
| Guerrero et al. | Analytical validation and reference intervals for freezing point depression osmometer measurements of urine osmolality in dogs | |
| Jones | Critical difference calculations revised: inclusion of variation in standard deviation with analyte concentration | |
| Kumar et al. | Medicare claim–based National Institutes of Health Stroke scale to predict 30-day mortality and hospital readmission | |
| Conigliani et al. | Prediction of patient-reported outcome measures via multivariate ordered probit models | |
| Landon et al. | The relationship between physician compensation strategies and the intensity of care delivered to Medicare beneficiaries | |
| Arina et al. | Mortality prediction after major surgery in a mixed population through machine learning: a multi‐objective symbolic regression approach | |
| Mardell et al. | Evaluation of a commercial in-house test kit for the semi-quantitative assessment of microalbuminuria in cats | |
| Nobel et al. | Index of cardiometabolic health: a new method of measuring allostatic load using electronic health records | |
| Lin et al. | The prediction value of Glasgow coma scale-pupils score in neurocritical patients: a retrospective study | |
| Korchia et al. | Total observed error, total allowable error, and QC rules for canine serum and urine cortisol achievable with the Immulite 2000 Xpi cortisol immunoassay |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: WELLNESS INDICATORS, INC., ILLINOIS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CALLEWAERT, DENIS;LYMAN, FRANK;SMITH, ROBERT;REEL/FRAME:027713/0961 Effective date: 20120214 |
|
| AS | Assignment |
Owner name: GREER, BURNS & CRAIN, LTD., ILLINOIS Free format text: LIEN;ASSIGNOR:WELLNESS INDICATORS, INC.;REEL/FRAME:030678/0614 Effective date: 20130501 |
|
| AS | Assignment |
Owner name: ESSEX ANGEL CAPITAL, INC., CANADA Free format text: DEFAULT JUDGMENT;ASSIGNOR:WELLNESS INDICATORS, INC.;REEL/FRAME:031283/0118 Effective date: 20130507 |
|
| STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |